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Abstract 
The studies performed in this dissertation have focused on the role of STAT5 signaling in 
macrophages during different environmental contexts. We have demonstrated that 
STAT5 controls macrophage function in the developing mammary gland by regulating 
aromatase expression and estrogen signaling. Using autochthonous and transplant models 
of mammary tumorigenesis, we have shown that STAT5 signaling regulates tumor-
associated macrophage function by modulating the expression of immunoregulatory and 
co-stimulatory molecules. Finally, these studies have revealed the ability of a clinically-
relevant JAK/STAT inhibitor to induce the expression of pro-tumorigenic factors in 
macrophages and have demonstrated the need to understand the effects of systemic 
therapies on other cells in the tumor microenvironment. 
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Chapter 1. Introduction 
Breast Cancer Overview 
Despite advances in treatment options, breast cancer remains the most commonly 
diagnosed cancer and the second-leading cause of cancer-related death among American 
women. In 2017 alone, it is estimated that over 250,000 American women will be 
diagnosed with breast cancer and more than 40,000 women will die as a result of the 
disease [1]. Clinically, breast cancers are typically characterized by the presence or 
absence of the hormone receptors, estrogen receptor (ER) and progesterone receptor 
(PR), and the human epidermal growth factor receptor 2 (HER2). Tumors that are found 
to be HER2+ are treated with therapies that specifically target HER2, such as the 
monoclonal antibody trastuzumab or small molecule tyrosine kinase inhibitors like 
lapatinib [2]. Tumors that express ER are treated with selective ER modulators, such as 
tamoxifen [3]. Additionally, aromatase inhibitors, which indirectly inhibit ER function by 
blocking the production of the ER ligand estrogen, are used to treat patients with ER+ and 
ER+/PR+ tumors [3,4]. However, the subset of breast cancers that are ER-/PR-/HER2- 
(known as triple negative breast cancer or TNBC) does not have any currently available 
and widely used targeted therapies [5]. Instead, women with triple negative-designated 
tumors have only systemic chemotherapy and surgery as treatment options. However, not 
all patients respond well to therapies when given based solely on the presence or absence 
of the hormone receptors and HER2, and the complexity and heterogeneity of breast 
cancer is not completely described with these markers alone. Since the pioneering study 
by Perou and colleagues in 2000, much research has been done using high-throughput 
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microarray-based global gene expression profiling and has resulted in the identification 
of several molecular intrinsic subtypes of breast cancer [6-11]. Currently, there are six 
distinct breast cancer intrinsic subtypes based on molecular profiling: luminal A, luminal 
B, normal breast-like, HER2-enriched, basal-like and claudin-low. Each subtype can be 
distinguished from the others based on gene cluster expression patterns and it has been 
proposed that each subtype arises from distinct progenitors.  
 
FGF/FGFR Signaling Axis in Breast Cancer 
The FGF/FGFR Axis 
One signaling pathway that has been implicated in the development of breast 
cancer is the fibroblast growth factor (FGF) signaling axis. The FGF family is comprised 
of 22 structurally similar ligands that mediate their effects through activation of four 
membrane-bound receptor tyrosine kinases [12]. Each FGF receptor (FGFR) contains 
three extracellular immunoglobulin (Ig)-like domains, an acidic box, a transmembrane 
domain, and a split intracellular tyrosine kinase domain (Figure 1.1A). Additionally, 
heparin or heparin sulfate proteoglycans are required to stabilize FGF to FGFR binding, 
and each receptor has an extracellular heparin-binding site [13,14]. Complexity of the 
FGF family arises not only because each ligand can bind multiple receptors but also 
because FGFR1-3 undergo alternative splicing. This alternative splicing occurs from the 
differential usage of two exons both coding for the C-terminal region of the third Ig-like 
domain resulting in either the IIIb or IIIc isoforms (Figure 1.1B). These splice variants 
are expressed in different tissues and have different ligand binding specificities. 
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Figure 1.1. Protein domain structure of the fibroblast growth factor receptor 
NH2 COOH
Ig I Ig II Ig IIIb /
Ig IIIc
Acidic
Box TM TKD 1 TKD 2
Exon 6 Exon 7 Exon 8 Exon 9 Exon 10
Exon 6 Exon 7 Exon 8 Exon 10 FGFR III-b
Exon 6 Exon 7 Exon 9 Exon 10 FGFR III-c
A.
B.
A) Protein domain structure of FGF receptor family members. Receptors contain 
an extracellular ligand binding domain, a transmembrane domain (TM), and two 
intracellular tyrosine kinase domains (TKD). The extracellular portion of the 
receptor is comprised of three immunoglobulin (Ig)-like domains and an acidic 
box. B) Alternative splicing of FGF receptor isoforms. Differential splicing of 
exon 8 or 9 leads to different Ig III domains (Ig IIIb / Ig IIIc). 
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In general, the IIIb isoforms are expressed in epithelial cells and the IIIc isoforms are 
expressed in mesenchymal cells [15]. Ligand binding to an FGFR monomer induces 
dimerization and subsequent transphosphorylation of tyrosine residues within the kinase 
domains [12]. Adaptor molecules, such as FGFR substrate 2 (FRS2) or phospholipase Cγ 
(PLCγ), bound to the activated receptor dimer can then be phosphorylated and activated, 
subsequently transmitting the FGFR activation signal through a variety of downstream 
molecules, including phosphoinositide-3 kinase (PI3K), extracellular signal-regulated 
kinase 1/2 (ERK1/2), various signal transducer and activator of transcription (STAT) 
proteins, and protein kinase C (PKC). This signaling cascade stimulates cellular 
processes such as proliferation, survival, migration, and angiogenesis. The FGF family 
has been widely studied and reviewed in normal and disease processes [12,15-18]. FGF 
signaling has been implicated in a variety of skin diseases as well as congenital skeletal 
disorders, such as Pfeiffer syndrome, in which a missense mutation in the third Ig-like 
domain of FGFR2 leads to autocrine activation of the receptor [19,20]. Of particular 
interest, FGF signaling has also been shown to be important in a number of malignancies, 
including prostate, endometrial, and breast cancer [17]. 
 
Alterations in the FGF/FGFR Axis in Breast Cancer 
Amplification of FGFR genes, including FGFR1 and FGFR2, was initially 
documented in human breast cancer samples in the early 1990s [21]. A surge of studies 
within the last 5-10 years has both confirmed these initial observations and expanded 
significantly upon the mechanisms through which the FGF/FGFR axis contributes to 
breast cancer [22,23]. In addition to gene amplification, increased protein expression of 
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both ligands and receptors, single nucleotide polymorphisms (SNPs) and mutations in 
FGFRs have been identified in human breast cancer cell lines and patient samples, 
suggesting that there are multiple mechanisms through which aberrant FGFR activation 
might occur.  
 
Amplification of a region at chromosome 8p12, which contains the FGFR1 gene, 
has been identified in approximately 10% of human breast cancers, with a range from 
8.7% to 22.8% depending on the study, and is associated with reduced metastasis free 
survival [24-26]. Furthermore, analysis of defined regions of the 8p12 amplicon 
demonstrated that a 1 Mb region within this amplicon that contains the FGFR1 gene is 
significantly associated with poor outcome [27]. Recent studies have demonstrated that 
amplification of FGFR1 correlates with increased expression of protein [28]. Studies of 
breast cancer cell lines harboring amplification of FGFR1 have shown that blocking 
FGFR activity leads to decreased growth and survival, demonstrating that FGFR1-
amplified cells become dependent upon aberrant FGFR1 activity[28]. Among the 
potential mechanisms through which amplified FGFR1 might lead to increased pathway 
activation are increased sensitivity of the amplified receptor to ligand or through 
abnormally high expression levels leading to ligand-independent activation. FGFR2 
amplification has been identified in 5-10% of human breast cancers [21], as well as in the 
SUM52-PE breast cancer cell line [29,30]. Subsequent work has demonstrated that 
FGFR2 is a transforming oncogene in mammary epithelial cells, which is capable of 
conferring an invasive phenotype to the cells [31].  
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Amplification of FGF ligands, including FGF3, FGF4 and FGF19, has also been 
observed in human breast cancer samples [32]. These ligands are located on chromosome 
11q13, which is amplified in 15% of human breast cancers [33]. In addition, FGF10 is 
located on chromosome 5p12, which is associated with 5-10% of breast cancers [34]. To 
date, it is unclear whether these ligands themselves have the capacity to drive tumor 
formation or if additional oncogenic changes are required. However, all of these ligands 
activate FGFR1 and/or FGFR2, which have both been strongly implicated in breast 
cancer. Interestingly, FGF3 and FGF4 bind to different isoforms (IIIb and IIIc isoforms, 
respectively) [34], suggesting that they may have different cell-type specific effects on 
the tumor cells and the cells residing in the microenvironment. In breast cancers, the 
11q13 amplicon, on which FGF3, FGF4 and FGF19 are found, is frequently co-
amplified with 8p12, where the FGFR1 gene resides [25]. This co-amplification suggests 
the existence of a potential loop in which increased expression of both ligand and 
receptor could contribute to these tumors, although this possibility remains to be 
investigated. Finally, there is a well-established cancer driver gene at the 11q13 
amplicon, CCND1 (cyclin D1) [33]. Whether these FGFs may be cooperating with cyclin 
D1 to further drive breast cancer remains to be determined. 
 
Another mechanism by which the FGF/FGFR axis may contribute to cancer is 
through increased protein expression of FGF ligands. For example, in human breast 
cancer tissues, immunohistochemical analysis demonstrated increased expression of 
FGF2 in 62% of basal-like breast cancers [35]. Furthermore, triple negative breast cancer 
cell lines secrete FGF2 in vitro, suggesting that the cellular source of the increased ligand 
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is likely the tumor cell itself [35]. In addition, FGF8 has been found to be increased in 
human breast cancers samples [36] and has also been found to be produced by breast 
cancer cells in culture [37]. Although the specific mechanisms leading to increased 
expression of these ligands in triple negative breast cancer cells remain unknown, recent 
studies demonstrated that treatment of the ER+ breast cancer cell line MCF-7 cells with 
estrogen leads to increased production of numerous FGF ligands, including FGF2, FGF4, 
FGF6, FGF7 and FGF9, providing a novel mechanistic link between aberrant FGFR 
activation and ER+ breast cancers [38]. Further studies are clearly required to understand 
both the mechanisms leading to increased FGF ligand expression and the specific 
contributions of the different FGF ligands to breast tumor formation and progression. 
 
Interestingly, large-scale genome wide association studies have identified SNPs 
specifically in intron 2 of the FGFR2 gene, which have been linked to increased breast 
cancer susceptibility [39,40]. Further studies have demonstrated that SNPs in FGFR2 
correlate with increased FGFR2 expression in breast tumors from patients homozygous 
for the risk allele [41]. While it remains unclear specifically how these SNPs contribute 
to breast cancer susceptibility, recent studies have explored potential mechanisms. For 
example, it was shown that SNPs can affect the binding affinities of specific transcription 
factors that regulate transcription of FGFR2 [41]. Results from a separate study 
demonstrated that two of the SNPs, rs2981582 and rs2981578, correspond with increased 
FGFR2 expression and activation of downstream signaling pathways in stromal 
fibroblasts, suggesting an alternative potential mechanism through which FGFR2 SNPs 
may contribute to increased breast cancer risk [42]. These observations raise the 
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interesting possibility that activation of FGFRs in non-tumor cells may contribute to 
breast cancer as well. 
 
Another potential mechanism of aberrant FGFR signaling is the presence of 
activating somatic mutations in FGFRs. Mutations in FGFR1 leading to constitutive 
tyrosine kinase activity are found in Type 1 Pfeiffer syndrome and other bone disorders. 
These mutations can occur in either the ligand binding domain or the tyrosine kinase 
domain. Somatic mutations have also been found in some lung cancers [43,44] and 
FGFR1 translocations have been identified in 8p11 myeloproliferative syndrome [45]. 
Furthermore, recent studies identified FGFR translocations in a variety of solid tumors, 
including lung cancer, bladder cancer, oral cancer, head and neck cancer, thyroid cancer 
and glioblastoma [46]. These translocation events contribute to cancer cell proliferation 
through oligomerization of FGFRs, suggesting that patients with cancers that harbor these 
translocations may be candidates for FGFR targeted therapies [46]. FGFR mutations have 
also been identified in human breast cancers. For example, FGFR2 mutations were 
identified in a kinome screen of metastatic breast cancer [47]. Furthermore, recent studies 
have identified somatic mutations in FGFR2 in breast cancer cell lines that confer 
constitutively activated signaling [48]. Current analysis of the Catalog Of Somatic 
Mutations In Cancer (COSMIC) database identifies limited numbers of mutations in 
FGFRs in breast cancer samples. Specifically, mutations are found in FGFR1 in 2 out of 
1031 samples (S125L, K566R), in FGFR2 in 1 out of 637 samples (R203C) and in 
FGFR4 in 1 of 550 samples (V550E) (Figure 1.2A). A SNP has also been identified in 
the transmembrane domain of FGFR4 (G388R), however the functional consequences of 
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NH2 COOH
TKD 1 ΔTKD 2
ZNF703 ex2
NH2 COOH
R203C**
K660N**
(S125L)*
(G388R)^ V550E^
(K566R)*
A.
B.
Figure 1.2. Map of known FGF receptor mutations linked with breast cancer 
A) Mutations in parentheses indicate that the mutation has not been experimentally shown to be an activating 
mutation. B) FGFR1-ZNF703 fusion identified in breast cancer samples in the COSMIC database. Exons 1-13 of 
FGFR1 are fused with exon 2 of ZNF703 (ZNF703 ex2), resulting in a truncation of the FGFR1 TKD2 (ΔTKD2) 
and fusion with ZNF703. *: FGFR1, **: FGFR2, ^: FGFR4. 
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this polymorphism remain to be described. Interestingly, analysis of the COSMIC 
database also reveals a possible fusion between FGFR1 and ZNF703 in a sequenced 
breast cancer sample, the latter of which has been suggested to be an oncogene for 
luminal B breast cancers [49] (Figure 1.2B). However, the functional relevance and 
frequency of this translocation in the breast cancer patient population remains to be 
determined.  Although somatic activating mutations are unlikely to be a common source 
of aberrant FGFR activity in breast cancers, they may still represent a potential targetable 
pathway in a small percentage of breast cancer patients and warrant further investigation. 
 
Association of Aberrant FGFR Activity with Breast Cancer Subtypes 
Aberrant activation of the FGF/FGFR axis has been implicated in many of the 
breast cancer subtypes, including the luminal B, HER2-enriched and basal-like subtypes 
[28,35,50,51]. Recent studies found that amplification of FGFR1 is frequently found in 
ER+ luminal B tumors and that tumors overexpressing FGFR1 exhibited increased 
proliferation and decreased distant metastasis-free survival [28]. Furthermore, ER+ breast 
cancer cell lines harboring FGFR1 amplification rely upon active FGFR signaling for 
anchorage independent growth [28]. Finally, these studies demonstrated that FGFR1 
amplification conferred resistance to endocrine-based therapies [28]. In another study, 
FGFR3 expression was found to be upregulated in tamoxifen-resistant breast cancers 
[52]. Further studies of breast cancer cells in vitro demonstrated that activated FGFR3 
could promote resistance to tamoxifen through downstream activation of PLCγ1 [52]. 
Together, these studies demonstrate a potential link between FGFR overexpression and 
hormone-responsive breast cancers and suggest that targeting FGFR activity may be a 
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rational therapeutic approach for breast cancers that are resistant to endocrine-based 
therapies. 
 
Comprehensive profiling of the different subtypes of breast cancers has 
demonstrated that HER2+ tumors have higher levels of expression of various receptor 
tyrosine kinases, including FGFR4 [7]. Furthermore, experimental studies using a 
lapatinib-resistant HER2+ breast cancer cell line demonstrated that amplification and 
overexpression of FGFR2 and targeting FGFR signaling using a receptor tyrosine kinase 
inhibitor PD173074 led to increased apoptosis of the cells [50]. Studies using mouse 
models of mammary tumors have demonstrated that combination therapies targeting both 
FGFR activation and HER2 activity are more effective than either therapy alone [51]. 
Together, these studies suggest that activated FGFR signaling may contribute to HER2-
driven tumor formation and resistance to therapy, and that combinatorial targeting of both 
pathways may have clinical relevance.  
 
Breast cancer subtype profiling has also demonstrated that FGFR1 and FGFR2 
are amplified in basal-like cancers [7]. Several basal-like breast cancer cell lines were 
found to be sensitive to inhibition of FGFR signaling using PD173074 [35]. Specifically, 
treatment of these cell lines led to decreased activation of ERK and Akt signaling and 
increased cell cycle arrest and apoptosis, demonstrating the dependence of these cells on 
FGFR activity [35]. One of the mechanisms of FGFR activation in these cells appears to 
be increased production of FGF2 ligand by the cancer cells, and further studies revealed 
that up to 62% of human basal-like breast cancers expressed FGF2 by 
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immunohistochemistry [35]. Thus, FGFR activation may be involved in a subset of basal-
like breast cancers as well.  
 
 While these recent studies have suggested that aberrant activation of the 
FGF/FGFR axis contributes to various subtypes of human breast cancers, further studies 
will be required to fully understand the actual percentage of FGFR-responsive and 
dependent breast cancers. Additionally, the development of reagents that can effectively 
detect activated FGFRs and FGF ligand expression in human breast cancer tissues will 
lead to a more thorough understanding of the numbers of breast cancer patients with 
FGFR-driven tumors. 
 
Function of FGFR Signaling in Tumor Formation and Progression 
Numerous studies using both in vitro and in vivo models have demonstrated a 
wide range of functions for FGFR signaling in breast tumor formation and progression. It 
has been well-established that FGFR stimulation in breast cancer cells results in 
proliferation and survival via activation of specific signaling pathways such as ERK and 
Akt [12]. More recent studies have focused on identifying novel mechanisms through 
which FGF/FGFR activation regulates breast cancer cells. For example, recent studies of 
ER+ breast cancer cells demonstrated that FGF9 can cooperate with estrogen to induce 
expression of the transcription factor TBX3, leading to expansion of the cancer stem cell 
population [38]. In other studies, microarray analysis was performed on ER- breast cancer 
cells treated with FGF8b to identify novel genes involved in mediating FGF-driven 
tumorigenesis [53]. Results from these studies demonstrated that FGF8b regulates the 
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expression levels of a number of genes involved in proliferation and survival, including 
BTG2, CCND1, CCNB1 (cyclin B), PLK1, survivin and aurora kinase A [53]. Using gene 
profiling approaches, it has also been shown that FGFR1 activation leads to increased 
expression of epidermal growth factor (EGF) family members, which then act on the 
tumor cells via ErbB family member activation to promote proliferation and migration, 
demonstrating a functional link between FGFR and ErbB activity in tumor cells [54,55]. 
Together, these studies demonstrate that FGFR activation leads to regulation of numerous 
different signaling pathways and transcriptional target genes. Identification of novel 
pathways that mediate FGFR-induced effects on breast cancer cells will ultimately lead to 
more rational design of therapeutic strategies targeting downstream FGFR activities. 
 
 While aberrant activation of the different receptors, including FGFR1, FGFR2 
and FGFR3, has been implicated in breast cancers as described above, the abilities of 
these receptors to function through either redundant or different mechanisms to promote 
breast cancer are not well understood. Comparison of inducible versions of FGFR1 and 
FGFR2 demonstrated differences in activation of downstream signaling pathways and 
receptor regulation [56]. Specifically, activation of inducible FGFR1 led to stronger and 
more stable activation of ERK than FGFR2. Furthermore, activation of inducible FGFR2 
led to rapid receptor downregulation in a Cbl-dependent manner, which was not observed 
following inducible FGFR1 activation [56]. Recent studies focusing on identifying the 
different effects of FGFR1, 2 and 3 knock-down on mammary tumor growth were 
performed in which each receptor was knocked down in breast cancer cells using short 
hairpin RNA (shRNA) strategies [57]. Decreased expression of FGFR1 led to smaller 
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tumors with less vasculature, demonstrating a critical role for FGFR1 in promoting these 
tumors [57]. Interestingly, decreased FGFR2 expression led to an increase in tumor size 
and vasculature compared with the control along with a significant increase in expression 
of FGFR1. These results suggest that decreased FGFR2 expression leads to a 
compensatory increase in expression of FGFR1 and subsequent tumor formation [57].  
Further studies of the differences between these receptors in promoting breast cancer are 
clearly required to determine the most effective methods for targeting specific FGFRs 
while avoiding compensation by the other receptors. 
 
 In addition to canonical activation of the transmembrane FGFR and subsequent 
receptor activation, recent studies have also demonstrated that FGFR1 can be cleaved by 
granzyme B [58]. Once cleaved, the intracellular portion of FGFR1 translocates to the 
nucleus where it contributes to the transcriptional regulation of genes that promote 
migration and invasion [58]. Interestingly, nuclear FGFR1 expression was also identified 
in human breast cancer samples, suggesting a novel mechanism for FGFR1-induced 
breast cancer [58]. Other recent studies of nuclear FGFRs have revealed the presence of 
FGFR2 in the nucleus of steroid-hormone responsive cells, where it interacts with other 
transcription factors, such as PR and STAT5, at progesterone response elements leading 
to regulation of expression of important oncogenes such as MYC [59]. Together, these 
studies demonstrate that cellular localization of FGFRs is an important consideration of 
their functions and further analysis of non-membrane bound forms of FGFRs may reveal 
novel mechanisms of action in promoting breast cancer.  
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 Analysis of mouse models has also demonstrated important roles for the 
FGF/FGFR axis in mammary tumor formation and progression. Expression of an 
inducible FGFR1 in mammary epithelial cells of transgenic mice using the mouse 
mammary tumor virus (MMTV) promoter was shown to lead to the formation of early 
stage epithelial lesions, demonstrating a driving role for FGFR1 activity in tumorigenesis 
[60]. Crossing these mice with the MMTV-Wnt1 mice led to a dramatic reduction in 
tumor latency, demonstrating the ability of FGFR1 to interact with other oncogenes to 
promote tumor formation [61]. In a separate study, Fgf2 knock-out mice were crossed the 
MMTV-PyMT transgenic mice, which form rapid and aggressive tumors [62]. 
Interestingly, loss of Fgf2 led to increased tumor latency and decreased tumor size, 
demonstrating that FGFR activation acts to promote tumor formation in this model. 
Finally, orthotopic transplant models using the well-studied 4T1 cells have demonstrated 
that growth and metastasis of 4T1 tumors can be inhibited using inhibitors of FGFR 
activity [63].  
 
While the discussion thus far has centered on autocrine activation of FGFR 
signaling either by increased expression of FGFRs or increased tumor cell production of 
FGF ligands, it is important to consider that stromal-derived FGFs may be capable of 
inducing FGFR activation in breast cancer cells. FGFs can be produced by a variety of 
cell types located in the stromal environment, including fibroblasts, endothelial cells and 
immune cells [64], raising the possibility that these cell types may contribute to aberrant 
FGFR activity in breast cancer cells in a paracrine manner. For example, recent studies 
demonstrated that FGF2 is highly expressed by carcinoma-associated fibroblasts in the 
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C4-hormone independent mammary tumor transplant model [65]. Furthermore, inhibition 
of FGFR in this model using PD173074 decreased tumor growth, demonstrating the 
contribution of stromal-derived FGFs to tumor formation [65]. These studies highlight 
the potentially complex nature of the mechanisms involved in driving FGF-dependent 
tumor formation and progression that are only beginning to be uncovered. 
 
In addition to the autocrine effects of FGFR activation on epithelial and tumor 
cell functions, FGFR activation in mammary epithelial cells and tumor cells can also 
contribute to profound changes within the stroma. Activation of an inducible FGFR1 in 
mammary epithelial cells in transgenic mice led to a rapid induction of angiogenesis in 
the mammary gland [60]. Furthermore, analysis of the same mouse model demonstrated 
that FGFR1 activation also induced a rapid inflammatory response characterized by 
increased levels of proinflammatory cytokines and macrophage recruitment [55]. 
Mechanistic studies found that activation of FGFR signaling in mammary epithelial cells 
led to the induction of soluble factors such as cytokines, chemokines and growth factors 
that can affect the surrounding stromal environment [55,66,67]. In another study, 
expression of a dominant negative FGFR2 construct in mouse mammary carcinoma cells 
resulted in decreased tumor growth and metastasis of 66c14 cells [68]. Further analysis of 
these tumors revealed that this decrease was accompanied by a decrease in 
lymphangiogenesis through suppression of vascular endothelial growth factor C (VEGF-
C) production [68]. Together, these studies suggest that effects of FGFR activation in 
tumor cells on the surrounding microenvironment may also be an important component 
of FGF-driven breast cancers. 
  17 
 
Therapeutic Targeting of FGF/FGFR in Breast Cancer 
The recent development of agents that target FGFR activity signifies a growing 
interest in targeting this pathway in the clinical setting. While pharmacological inhibition 
of FGFR activity has been used extensively in pre-clinical studies, new classes of 
receptor tyrosine kinase inhibitors have been developed that either selectively target 
FGFR or target FGFR in addition to other receptor tyrosine kinases [16]. As discussed 
below, a number of these agents are currently being examined in clinical trials for breast 
and other cancers (Table 1.1). While this discussion will focus primarily on approaches to 
specifically target breast cancers, it is important to note that there are a number of other 
FGFR-targeted approaches being examined at both the pre-clinical and clinical stages in a 
variety of cancers [16].  
 
 Of the selective FGFR tyrosine kinase inhibitors, NVP-BGJ398 and AZD4547 are 
currently being tested in clinical trials. NVP-BGJ398 was developed as an orally 
bioavailable selective pan-FGFR inhibitor with potent anti-FGFR activity in the 
nanomolar range [69]. Further studies using this small molecule inhibitor demonstrated 
that genetic alterations in FGFR could be used as biomarkers to predict sensitivity to 
NVP-BGJ398 [70]. Specifically in breast cancer, FGFR1 amplification in cell lines 
correlated with increased responsiveness to NVP-BGJ398 [70], suggesting that patients 
with breast cancers that harbor FGFR1 amplification may benefit from this therapeutic 
agent. A phase I dose escalation trial is currently recruiting patients to determine the 
maximum tolerated dose and safety profile of NVP-BGJ398 in patients with advanced 
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Table&1.&Current&state&of&FGF/FGFR5targeted&therapies&in&breast&cancer
Drug&Name Manufacturer Target(s) IC50&(nM) Development&Stage
NVP$BGJ398 Novartis FGFR1$3 9.96$613.9 Phase6I6$6NCT010042246(Recruiting)
FGFR4 391.5
VEGFR2 1019.0
AZD4547 AstraZeneca FGFR1$3 0.26$62.5 Phase6IIa6$6NCT012025916(Recruiting)
VEGFR2 24.0 Phase6IIa6$6NCT017919856(Recruiting)
FGFR4 165.0 Phase6II6$6NCT017957686(Recruiting)
TKI258 Novartis FLT3 1.0 Phase6II6$6NCT009589716(Completed)
(dovitinib) c$KIT 2.0 Phase6II6$6NCT012620276(Recruiting)
FGFR1$3 8.06$69.0
VEGFR1$3 10.06$613.0
PDGFRa/b 27.06$6210.0
E$3810 Ethical6Oncology6Science CSF$1R 5.0 Phase6I6$6NCT012839456(Recruiting)
VEGFR1$3 7.06$625.0
FGFR1$2 17.56$682.0
FP$1039 Five6Prime6Therapeutics FGF6Ligands $ Phase6I6$6NCT006875056(Completed)
(FGFR1:Fc)
Table 1.1. Current state of FGF/FGF receptor targeted therapies in breast cancer 
Status current as of May 2013. 
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 solid tumors with amplification of FGFR1 and FGFR2 or mutation of FGFR3 
(NCT01004224).  
 
 AZD4547 was also recently developed as a selective FGFR tyrosine kinase 
inhibitor [71]. AZD4547 exhibits efficacy against FGFR1, FGFR2 and FGFR3, with 
weaker activity against FGFR4 and 120-fold increased sensitivity over VEGF receptor 
(VEGFR) [71]. Pre-clinical studies demonstrated effective FGFR inhibition in a panel of 
cancer cell lines, including the FGFR2-expressing breast cancer cell line SUM52-PE 
[71]. Several trials are currently recruiting patients to examine safety and efficacy of 
AZD4547, three of which specifically include breast cancer patients. NCT01202591 is a 
Phase IIa clinical trial in which patients with ER+ breast cancer with either FGFR1 
polysomy or gene amplification that have progressed following endocrine-based therapy 
are being recruited to test the safety and efficacy of AZD4547 with fulvestrant compared 
with fulvestrant alone. NCT01791985 is a Phase IIa study in which ER+ patients whose 
tumors have progressed despite previous treatment with anastrozole or letrozole are being 
recruited. Once dosage of AZD4547 is established, patients will receive either 
exemestane alone or AZD4547 with letrozole or anastrozole. Finally, a third trial is 
recruiting patients with breast, gastric, esophageal and squamous cell lung carcinomas 
with amplified FGFR1 or FGFR2 and progression following chemotherapy. Safety and 
tolerability will be monitored and response to AZD4547 will be assessed by analyzing 
ERK phosphorylation and tumor size (NCT01795768). While clearly still in early phases 
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of testing, important information regarding selective targetability of FGFR activity in 
breast cancer patients will likely be obtained from these trials. 
 
 There are a number of tyrosine kinase inhibitors that bind and inhibit multiple 
kinases in addition to FGFR and are thus termed non-selective tyrosine kinase inhibitors. 
An example of a non-selective tyrosine kinase inhibitor being tested in clinical trials is 
TKI258 (dovitinib). TKI258 inhibits a broad panel of receptors including VEGFR, FGFR 
and platelet-derived growth factor receptor (PDGFR) and has demonstrated good efficacy 
in inhibiting tumor growth in pre-clinical models of mammary tumor formation [51,63]. 
TKI258 is currently being evaluated in numerous clinical trials for various cancers. 
Specifically related to breast cancer, a completed study evaluated the safety and efficacy 
of TKI258 in HER2- metastatic breast cancer (NCT00958971). In addition, a more recent 
Phase II study is currently recruiting patients to test TKI258 in HER2- inflammatory 
breast cancers (NCT01262027).   
 
A number of other non-selective receptor tyrosine kinase inhibitors that show 
efficacy against FGFRs have been recently developed and examined in pre-clinical 
studies. For example, recent studies demonstrated that a novel inhibitor, E-3810, inhibits 
VEGFR1, VEGFR2, VEGFR3, FGFR1 and colony stimulating factor 1 receptor (CSF1R) 
with inhibition of FGFR2 at higher concentrations [72]. Studies using an MDA-MB-231 
xenograft model demonstrated that treatment with E-3810 alone led to tumor stabilization 
[72]. Furthermore, combination treatment with paclitaxel led to tumor regression and was 
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well-tolerated [72].  In another recent study, AP24534 (ponatinib), which was initially 
identified as a potent inhibitor of BCR-ABL, was also found to inhibit growth of breast 
cancer cell lines in vitro [73]. Furthermore, AP24534 inhibited phosphorylation of FGFR 
in breast cancer cell lines that harbor amplifications of FGFR1 and FGFR2, suggesting 
specific inhibition of FGFR activation [73]. Although further studies are required to 
determine the utility of these types of inhibitors in FGFR-driven patient tumors, the 
results from these experimental studies suggest that these types of non-selective 
approaches certainly warrant further investigation. 
 
 Although many of the efforts to target FGFR activation have focused on 
developing inhibitors of FGFR kinase activity, several other approaches of inhibiting the 
FGF/FGFR axis have also been investigated. The use of antibody-based therapy in breast 
cancer has been successful for targeting other receptors, such as HER2 [2]. Therefore, the 
development of antibodies that bind and inhibit specific FGFR isoforms seems to be a 
rational approach to targeting the FGFR pathway. Recent studies describe the 
development of an antibody, GP369, which specifically recognizes the FGFR2-IIIb 
isoform [74]. The GP369 antibody was effective in blocking proliferation of FGFR2-
amplified cell lines, including the SUM52-PE breast cancer cells in vitro [74]. 
Furthermore, GP369 induced tumor stasis of MFM-223 breast cancer xenografts in vivo 
[74]. These studies provide strong rationale for further studies aimed at targeting specific 
FGFR isoforms. In an earlier study, however, a single chain antibody to the FGFR1-IIIc 
isoform was found to be anorexigenic when administered to mice [75]. Whether this 
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approach might be more effective using a different isoform that is not as widely 
expressed as FGFR1-IIIc remains to be determined.  
 
 Another potential approach for targeting the FGF/FGFR axis is the development 
of strategies that specifically target the ligands. In a recent study, long pentraxin-3 
(PTX3), a soluble pattern recognition receptor, was shown to be capable of binding and 
inhibiting specific FGF ligands, including FGF2 and FGF8b [76-78], both of which have 
been implicated in breast cancer as described above. Expression of PTX3 in hormonally-
responsive mouse mammary tumor cells led to decreased proliferation in vitro as well as 
decreased angiogenesis and tumor growth in vivo [78]. Recently, a ligand trap (FP-1039) 
consisting of the ligand-binding domain of FGFR1 fused to an Ig-Fc domain has shown 
antitumor activity in pre-clinical models [79]. This effect was most evident against 
tumors with an upregulation of FGF/FGFR signaling axis. A Phase I clinical trial 
(NCT00687505) was recently completed in patients with advanced solid tumors and 
while not specific to breast cancer, these results suggest that targeting FGF ligands 
represents a feasible therapeutic approach. 
 
As discussed above, experimental studies have suggested that inhibiting FGFR 
activity may enhance tumor responses to other established drugs, such as endocrine-based 
therapies and ErbB-targeted therapies [28,51]. Furthermore, FGFR activation also 
promotes resistance to chemotherapeutic-based treatments (Lindsey Bade, unpublished 
observations). Therefore, it is possible that combination therapies using FGFR inhibitors 
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along with standard treatments may lead to better responses in patients with high levels of 
FGFR activity. In addition, as further studies continue to reveal the mechanisms that 
drive breast cancer, more potential opportunities for developing effective combination 
therapies involving FGFR inhibition can be considered. For example, due to the high 
prevalence of mutations in PIK3CA in breast cancer [7], combining FGFR inhibitors with 
inhibitors of the PI3K/Akt pathway seems to be a logical combination. In fact, combined 
inhibition of FGFR2 and mammalian target of rapamycin (mTOR) was found to be an 
effective therapy in endometrial models [80]. Further studies are required to determine 
whether this combination might also be effective for breast cancer, although the recent 
interest in using mTOR inhibitors in breast cancer makes this an attractive possibility 
[81]. In addition, recent studies of renal cancer have suggested that FGF can regulate 
endothelial cell proliferation and tubule formation even in the presence of the VEGFR 
inhibitor sunitinib, and that blocking FGF2 can enhance the anti-VEGFR effects [82]. 
While these studies have yet to be performed in the context of breast cancer, these studies 
demonstrate the feasibility of targeting FGFR in combination with other targeted 
therapies and warrant further investigation into the complex interactions through which 
FGFR mediates in pro-tumorigenic effects in breast cancer. 
 
Development of the Mouse Mammary Gland 
Normal Mammary Gland Development 
In many instances during tumor development, cancer cells exploit developmental 
pathways to promote their own growth. These processes, which in some cases have been 
inactive for decades, are reactivated to provide growth factors and stimuli not typically 
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produced in the normal environment [83-85]. Thus, by further characterizing the 
processes involved in normal mammary gland development, we will gain valuable insight 
into mechanisms by which they are co-opted during tumorigenesis. Beginning early in 
embryogenesis, patterning of the mammary glands occurs with the specification of the 
sites of the developing glands [86-88]. As development continues, epithelial cells 
invaginate into the surrounding mesenchyme and form the mammary bud. Just prior to 
birth, the cells begin to proliferate and allow the bud to invade into the adjacent fat pad. 
Once this has occurred, the mammary epithelial cells (MECs) begin a process of ductal 
morphogenesis to generate a rudimentary ductal tree [89,90]. A prominent structure in 
pubertal mammary gland development is the terminal end bud (TEB), the site of actively 
proliferating epithelial cells. These organized structures are found at the distal end of the 
mammary ducts and contain cap cells and body cells, which give rise to cells of the 
myoepithelial and luminal lineages respectively [91,92]. As the cells proliferate, the 
TEBs advance through the fat pad until they reach the edge, at which time they regress to 
form the terminal ducts. At this point, side branching occurs to create secondary and 
tertiary ducts from the main ducts to fill the entire fat pad laterally. The mammary gland 
undergoes large-scale expansions and regressions during repeated estrous cycles, with 
new epithelial buds sprouting from the ducts and subsequently disappearing as estrogen 
and progesterone levels rise and fall [93,94]. During pregnancy, however, these hormone-
induced changes stop being cyclical and the gland enters a state of preparation for 
lactation. Alveolar buds form in response to prolactin and develop into mature alveoli to 
produce milk [95,96]. After weaning, the mammary gland must return to its resting, pre-
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pregnancy state through a tightly-regulated process of programmed cell death called 
involution [97]. At this time, the mammary gland begins to expand and regress again 
during estrous cycles and is ready to expand again in response to another pregnancy. 
 
During postnatal development, numerous cytokines and hormones regulate further 
growth of the mammary gland. Previous work has shown that the cytokines interleukin-4 
(IL-4) and IL-13 are critical for promoting the differentiation and maturation of luminal 
epithelial cells [98]. Additionally, the requirement of ER and PR signaling in pubertal 
development has been demonstrated through elegant tissue recombination studies. While 
embryonic development is unaffected, mammary glands of ERα-null mice fail to elongate 
through the fat pad during pubertal development and lack defined TEBs [99]. Despite this 
lack of outgrowth, ERα-null epithelium is still responsive to progesterone and form 
alveoli during pregnancy. The requirement of ER signaling is limited to the epithelial 
cells, as transplantation of wild-type MECs into an ERα-null fat pad results in normal 
ductal morphogenesis [99]. Additional studies have shown a differing role for PR 
signaling, with transplantation of PR-null MECs into wild-type fat pad resulting in the 
formation of a normal ductal tree [100]. As expected however, PR-null MECs fail to 
respond to progesterone during pregnancy and do not form alveolar structures. 
Intriguingly, transplantation of wild-type MECs into a PR-null fat results in a modest 
defect in ductal outgrowth, suggesting a role for PR signaling in stromal cells regulating 
MEC proliferation in a paracrine manner [100]. Notably, ER and PR signaling promote 
MEC proliferation in a paracrine manner, with previous reports demonstrating that 
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proliferating cells are not contained within the ER+ or PR+ compartments [101-103]. 
Hormone signaling is a tightly regulated process, with any deviations above or below the 
optimal levels resulting in similar defects. Exposure to exogenous estrogen treatment 
results in decreased ductal elongation, similar to results seen in ERα-null MEC 
transplants, however, estrogen treatment also leads to increased lateral branching [104]. 
Thus, keeping hormone levels and signaling within a specified range is of critical 
importance for maintaining mammary gland integrity. 
 
FGF/FGFR in Normal Mammary Gland Development 
In order to understand how aberrant FGFR activation might contribute to breast 
cancer, it is first important to consider the functions of FGFR in normal mammary gland 
development. FGF signaling has been linked to many developmental processes, including 
formation of limb buds, stimulation of angiogenesis, and induction of branching 
morphogenesis in organs such as the kidneys, lungs, prostate, and mammary glands [105-
110]. During embryonic mammary gland development, FGF10 and its receptor FGFR2-
IIIb are essential for proper mammary placode formation as shown by analysis of mice 
lacking these genes [111,112].  
 
More recent studies have focused on the contributions of FGFR to postnatal 
mammary gland development [113,114]. FGFR2 expression is required within the 
mammary epithelium during pubertal ductal morphogenesis, as Cre-mediated deletion of 
Fgfr2-IIIb within the epithelium results in reduced ductal morphogenesis and a lack of 
terminal end buds [113]. Interestingly, while FGFR2 is expressed in the epithelial cells, 
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its ligand (FGF10) is highly expressed in the mammary fat pad, suggesting that FGFR2 
activation is regulated via a paracrine mechanism. Furthermore, recent studies in which 
Fgfr1 and Fgfr2 were deleted in the epithelium led to inhibition of ductal outgrowth and 
a decrease in the repopulating cell population, suggesting a role for FGFR signaling in 
maintenance of the stem cell population in the mammary gland [114]. Together, these 
studies demonstrate the importance of the FGF/FGFR signaling axis during both 
embryonic and mammary gland development. The specific mechanisms of FGFR 
function in the mammary epithelium, including promotion of proliferation and stem cell 
function, suggest potential mechanisms through which aberrant FGFR signaling might 
contribute to tumor formation and progression.  
 
Macrophages Regulate Mammary Gland Development 
Overview of Macrophages 
As a cell of the innate immune system, macrophages play critical roles in both 
host defense against pathogens and proper tissue development. During embryonic 
development, a population of macrophages derived from yolk sac hematopoiesis can be 
found throughout the organism and are thought to contribute to the populations of tissue-
resident macrophages in the adult. This process occurs prior to the induction of 
hematopoiesis in the bone marrow, strongly suggesting a unique origin and function for 
these embryonic macrophages [115,116]. Additionally, embryonically-derived, tissue-
resident macrophages have been found in a diverse array of organs and tissues and have 
been shown to self-maintain locally independent of monocyte precursors [117]. 
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Postnatally, however, the multi-step differentiation program that leads to mature 
macrophages begins in the bone marrow with hematopoietic stem cells (HSCs) [118]. 
These c-kit+/Sca-1+/Lineage(Lin)- HSCs give rise to two distinct multipotent progenitor 
populations: the c-kit+/Sca-1+/Lin-/IL-7Rα+ common lymphoid progenitor (CLP), which 
differentiate into B cells, T cells, NK cells and a subset of dendritic cells (DCs), and the 
c-kit+/Sca-1-/Lin-/IL-7Rα- common myeloid progenitor (CMP), which can populate the 
erythrocyte, megakaryocyte, myeloid-derived DC, granulocyte and monocyte 
compartments [118,119]. More specific precursors of the monocyte/macrophage lineage 
have been identified, including the c-kit+/Lin-/CX3CR1+ monocyte-macrophage DC 
progenitor (MDP) that give rise to both monocytes and dendritic cells [120]. Recent work 
has also identified a CD135-/Ly6C+ committed progenitor derived from the MDP that is 
restricted to the monocyte-macrophage lineage [121]. Mature CD11b+/CD115+ 
monocytes can then enter the circulation in order to be distributed around the body. 
Circulating monocytes are a heterogeneous population themselves, consisting of so-called 
“patrolling monocytes” and “inflammatory monocytes” [122]. Patrolling monocytes are 
responsible for crawling along the luminal side of the endothelium to monitor for danger-
associated molecular patterns (DAMPs), and upon encountering such a signal, rapidly 
entering the tissue and beginning to recruit additional effector cells and start a productive 
immune response [123]. A major function of inflammatory monocytes is to respond to 
sites of inflammation and tissue damage and monocytes are recruited to these sites by 
following a variety of chemokine gradients, the most well-characterized of which being 
chemokine (C-C motif) ligand 2 (CCL2) [124,125]. Upon arriving in the vasculature near 
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the site of inflammation, monocytes begin a process of rolling adhesion in which selectin 
molecules on the surface of the endothelial cells bind to selectin ligands on the 
monocytes [126,127]. These interactions then allow tight binding to occur between 
vascular cell adhesion molecule 1 (VCAM1) on the endothelium and integrin molecules 
on the monocytes [128-130]. Finally, the monocytes are arrested and can exit the 
circulation and enter the inflamed tissue, a process known as diapedesis [126]. Once in 
the tissue, monocytes can be further differentiated to macrophages in the presence of 
colony stimulating factor-1 (CSF-1) to carry out effector functions involved in pathogen 
clearance, wound healing and developmental regulation [131,132]. 
 
Macrophages are a cell type with exquisite plasticity and are able to carry out a 
diverse array of functions. In order to accomplish this, macrophages respond to signals 
from cytokines, chemokines, growth factors and pathogen-derived factors in the 
microenvironment. In the early stages of an infection, macrophages are activated by 
interferons produced by infected cells and by bacterial-derived compounds such as 
flagella, lipopolysaccharide (LPS) and unmethylated CpG motifs [133-135]. These 
signals typically induce a pro-inflammatory response in macrophages to limit pathogen 
spread and recruit additional innate and adaptive immune cells to the site of infection. 
After the infection has been controlled and the pathogen cleared, macrophages are 
instrumental in the resolution of inflammation to prevent further tissue damage. 
Cytokines such as IL-4 and IL-13 can promote an anti-inflammatory response in 
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macrophages to block additional activation of immune cells in the tissue and promote 
tissue remodeling and collagen deposition [136,137]. 
 
Macrophages in the Developing Mammary Gland 
In addition to their roles in pathogen clearance and wound healing, macrophages 
can also respond to cytokines present in the tissue microenvironment during 
development, where complex and reciprocal interactions take place between epithelial 
and stromal cells. One particular site where such interactions take place is in the 
developing mammary gland. As a cell type that serves to act as a first line of defense 
against foreign substances and pathogens, it is only logical to have macrophages 
dispersed throughout the body. But in addition to their role as immunological surveyors, 
macrophages also play critical roles in regulating mammary gland development. Previous 
studies have indicated that macrophages are found in close association with MECs at 
many well-characterized stages of mammary gland development [138]. Immunostaining 
of mammary glands for the macrophage marker F4/80 indicates the presence of 
macrophages surrounding the body cells of the TEB [138,139]. These macrophages are 
poised to phagocytose cellular debris from MECs undergoing apoptosis while generating 
the hollow lumen of the mammary ducts [140]. At maturity, macrophages can be found 
lining the mammary ducts where they promote epithelial cell proliferation and 
differentiation through production of growth factors, chemokines and inflammatory 
mediators. During lactation, F4/80+ macrophages have been observed in close proximity 
to the alveoli and are a major cellular component of milk [138,139,141]. Once lactation is 
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completed and weaning occurs, the mammary gland undergoes involution to return to its 
pre-pregnant state, involving large amounts of apoptosis and extracellular matrix (ECM) 
remodeling. Again, macrophages are major contributors to this process, phagocytosing 
apoptotic cellular debris and producing matrix remodeling factors to facilitate the 
transition back to the fully-involuted state [142,143].  
 
Numerous studies have been undertaken using genetic and biochemical 
approaches to deplete macrophages during mammary gland development. Mice 
homozygous for a null mutation in CSF-1, the critical factor required for macrophage 
differentiation, show significant impairment in ductal elongation during mammary gland 
development [144]. This defect can be rescued through the use of a tetracycline-inducible 
transgene to re-express CSF-1. Architecturally, organization of collagen I into long fibers 
around the neck of the TEBs is impaired in CSF-1-deficient mice while total collagen I 
deposition is unaffected, implicating a specific role for macrophages in regulating 
collagen organization but not collagen biosynthesis [145]. The contributions of 
macrophages to estrous-cycle induced changes were described elegantly using the 
CD11b-DTR inducible mouse model of macrophage depletion. Macrophages are found at 
different frequencies in the mammary gland during the estrous cycle, reaching a 
maximum during diestrus. Depletion of macrophages resulted in a nearly 50% reduction 
in alveolar bud formation in response to progesterone treatment and an overall decrease 
in MEC proliferation [146]. Additional work using sub-lethal irradiation has 
demonstrated that cells of the hematopoietic lineage are required for the formation of 
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TEBs during pubertal development and that macrophages modulate their 
immunostimulatory profile over the course of the estrous cycle [140,147].  
 
While these studies clearly demonstrate a role for macrophages is regulating 
mammary gland development, the mechanism by which this occurs remains unclear. One 
possible mechanism is that macrophages in the microenvironment respond to the same 
cytokines and growth factors required for epithelial cell development and respond in a 
unique way. IL-4 and IL-13 have been implicated in mammary epithelial cell 
differentiation and are found at measureable amounts in the developing mammary gland 
[98]. When exposed to these cytokines, macrophages respond by producing a host of 
anti-inflammatory factors and tissue remodeling agents known to be needed during 
mammary gland development. Studies of macrophages in infection models have 
illustrated that tissue-resident macrophages are more predisposed to an anti-inflammatory 
response compared to monocyte-derived macrophages recruited from the circulation 
[148,149]. Transforming growth factor-beta (TGF-β) and members of the matrix 
metalloproteinases (MMP) family are produced by macrophages at high levels in 
response to IL-4/IL-13 stimulation in vitro [133,150]. In the setting of the mammary 
gland in vivo, MMPs are required to degrade and remodel the ECM to allow further 
ductal elongation to occur through the fat pad, while TGF-β plays a suppressive role to 
limit the extent of ductal branching [151-154]. Thus, it is possible that IL-4 and IL-13 
play dual roles in the microenvironment: promoting MEC differentiation and stimulating 
tissue-resident macrophage function. While ductal elongation is driven primarily by 
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ovarian-produced estrogen, studies in breast cancer have shown that macrophages 
themselves are capable of producing estrogen locally through the expression of the 
estrogen synthesizing enzyme aromatase [155]. There is a relative lack of knowledge to 
date regarding the role of macrophage-produced estrogen, but it is tempting to speculate 
that macrophages associated with the TEBs or lining the mammary ducts could regulate 
development and proliferation directly by creating pools of locally-concentrated estrogen. 
Further studies are warranted to determine if macrophages express aromatase in vivo and 
how the resulting rise in estrogen levels in the mammary gland affects development. In 
addition, the increased estrogen and proliferative signals in the mammary gland may also 
help establish a pro-tumorigenic environment, in which the MECs are primed for the 
tumor initiation when exposed to an oncogenic insult. Understanding how changes that 
take place in the mammary gland during development can affect tumor initiation at a later 
point in life is critical in developing preventative strategies through life-style changes and 
therapeutic intervention. 
 
Inflammation Influences Tissue-Resident Macrophage Function 
Recent evidence has supported the long-postulated idea that chronic inflammation 
enhances the risk of developing cancer [156-159]. Furthermore, diseases with systemic 
inflammatory components are major risk factors for certain types of cancer, including 
breast cancer [156,160]. In patients with Crohn’s disease, increased expression of the 
pro-inflammatory cytokine tumor necrosis factor-alpha (TNFα) recruits inflammatory 
macrophages and leads to the production of additional pro-inflammatory factors, 
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initiating a feed-forward loop which leads to tissue damage and predisposition to 
oncogenic initiation [161]. One of the most common diseases associated with cancer risk 
is obesity, with 34.9% of adults in the United States being classified as obese [162]. 
Patients with obesity often have elevated serum levels of pro-inflammatory molecules, 
such as IL-6, which induce a systemic chronic inflammatory state [163]. In the mammary 
gland microenvironment specifically, obesity is directly linked with increased IL-6 
signaling and increased macrophage recruitment compared to normal-weight 
mammoplasty specimens [164]. In a resting state, the amount of pro-inflammatory and 
anti-inflammatory signals are maintained in a state of equilibrium (Figure 1.3). However, 
in pathologic settings such as obesity, inflammatory homeostasis is lost and the balance is 
tipped in favor of pro-inflammatory factors. In these cases, the increased abundance of 
pro-inflammatory factors relative to anti-inflammatory factors affects cells in the 
microenvironment. Once macrophages are exposed to pro-inflammatory factors they 
upregulate the production of additional pro-inflammatory factors, creating a feed-forward 
loop that further upsets inflammatory homeostasis. It is interesting to speculate why 
obese patients with increased levels of IL-6 have a predisposition to developing ER+ 
breast cancers specifically [165]. Studies focused on endometrial carcinoma have 
revealed a paracrine signaling axis whereby cancer cells produce IL-6 to stimulate 
stromal cells to upregulate aromatase and produce estrogen, thus inducing a cycle of 
increased cancer cell proliferation and IL-6 production [166]. It remains to be seen if a 
similar axis exists in breast cancer, but with their role in regulating mammary gland 
development, it is not difficult to hypothesize that macrophages may upregulate  
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aromatase expression in response to IL-6 in the context of obesity, thus providing a 
mechanistic explanation of the propensity for obese women to develop ER+ breast 
tumors.  
 
In addition to pathologic inflammatory conditions, acute inflammatory responses 
in the context of normal tissue processes can have profound impacts on the 
microenvironment. In the 5-year period following childbirth women are susceptible to 
developing postpartum breast cancer with a particularly poor prognosis [167]. Elegant 
xenograft studies in mice have revealed that the microenvironment of the involuting 
mammary gland significantly enhances tumor growth compared to nulliparous mammary 
glands [168]. Most recently, an overall profile was created to determine the relative 
abundance of immune cells during the process of involution compared to nulliparous and 
lactating glands. While modest changes were observed in DC recruitment at all time 
points of involution, a near 10-fold increase in macrophage recruitment is observed 
during the first week of involution and remains elevated at 4 weeks after weaning [142]. 
This increased macrophage recruitment was accompanied by increased CD4+ and CD8+ T 
cell recruitment and an increased presence of FOXP3+ regulatory T cells. 
Mechanistically, the microenvironment of the involuting mammary gland induces 
macrophages to take on an immunosuppressive profile by producing IL-10 and 
suppressing T cell activation [142]. This acute disruption of inflammatory homeostasis 
results in the formation of a pro-tumorigenic niche through direct suppression of adaptive 
immunity. A better understanding of the critical balance between pro-inflammatory and 
  37 
anti-inflammatory factors is clearly needed in order to develop new therapeutic regimens 
for the treatment and even prevention of breast cancer. 
 
Macrophages in the Tumor Microenvironment 
Tumor-Associated Macrophages 
In addition to their contributions to normal mammary gland development, 
macrophages are well-established constituents of the breast tumor microenvironment. 
Increased macrophage density in pretreatment biopsies of breast cancer patients 
correlates with reduced recurrence-free and overall survival [169-171]. Therefore, efforts 
have focused on understanding the mechanisms through which macrophages contribute to 
breast cancer growth and progression and these topics have been reviewed extensively 
[133,150,172-174]. Myeloid cells in the tumor microenvironment, in particular 
macrophages, have been shown to contribute to tumor growth and progression in a 
variety of ways. Tumor-associated macrophages (TAMs) secrete soluble factors, such as 
vascular endothelial growth factor (VEGF), which induce angiogenesis and partially 
relieve the hypoxic stress within fast-growing tumors [175]. In addition to promoting 
angiogenesis, TAMs support tumor cell survival, migration, and invasion through the 
secretion of growth factors such as EGF and FGFs and chemokines such as CXCL1/2 
[67,176-178]. In recent studies using intravital imaging techniques, Lohela et al. 
demonstrated that prolonged depletion of myeloid-derived cells in a model of breast 
cancer resulted in delayed tumor growth, decreased angiogenesis, and fewer lung 
metastases [179]. Furthermore, production of growth factors and ECM remodeling by 
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TAMs have been implicated in promoting breast cancer resistance to chemotherapeutic 
agents such as paclitaxel, doxorubicin, and etoposide [180]. Finally, numerous studies 
have provided evidence of TAMs interacting with cells of the adaptive immune system, 
mainly CD4+ and CD8+T lymphocytes, and both directly and indirectly suppressing their 
antitumor effects [181-183]. 
 
Understanding macrophage functions in the context of normal tissue development 
can provide insights into the functions of macrophages during tumor growth and 
progression. Specifically, there are parallels between the mechanisms of macrophage 
recruitment and macrophage-mediated alterations in ECM in both the normal mammary 
gland and the tumor microenvironment. Furthermore, it is becoming clear that the 
balance between pro-inflammatory and anti-inflammatory factors is key to the regulation 
of macrophage function within the tumor microenvironment. Therefore, further 
discussion will focus on macrophage recruitment, polarization, and regulation of ECM 
within the tumor microenvironment. 
 
As mentioned above, CCL2 and CSF-1 are important for both recruitment and 
differentiation of macrophages in the normal mammary gland. Likewise, these factors 
have been implicated in recruitment of macrophages to both primary and metastatic 
tumor sites. Using genetic approaches, seminal studies demonstrated that CSF-1 is 
critical for macrophage recruitment and differentiation in tumor microenvironment of 
MMTV-PyMT mice [184]. These studies demonstrated that reduced macrophage 
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infiltration significantly reduced the ability of the tumor cells to metastasize to the lung. 
Tumor cell-derived CSF-1 has also been linked to the proliferation of a pro-tumor subset 
of CD11blo F4/80hi macrophages in the MMTV-Neu transgenic model of mammary tumor 
growth [185]. In these studies, administration of the CSF-1R inhibitor GW2580 to tumor 
bearing mice drastically reduced the numbers of CD11blo / F4/80hi macrophages in S 
phase. These, and other recent studies, suggest that in addition to recruitment of 
monocytes from the bloodstream, certain TAM populations are able to proliferate within 
the tumor microenvironment [185-187]. Taken together, these studies indicate that 
therapies aimed at targeting the accumulation and/or proliferation of TAMs may improve 
clinical outcomes for breast cancer patients, and as a result CSF-1R inhibitors and 
blocking antibodies have entered clinical trials for various cancer types, including breast 
cancer. In a recent report, Ries et al. described a significant depletion of CD68+ / 
CD168+ macrophages in a small cohort of breast cancer patients and among those 
receiving the highest protocol dose, analysis revealed a switch of lymphocyte infiltrates 
from CD4+ T cells before treatment to CD8+ T cells after treatment [188]. This study 
provides proof-of-principal that blockade of the CSF-1/CSF-1R pathway results in fewer 
macrophages recruited to human breast tumors, and this change in myeloid recruitment 
affects the overall composition of the tumor microenvironment. 
 
Another key chemokine that has been implicated in macrophage recruitment to 
the tumor microenvironment is CCL2/MCP-1. Numerous studies have found that tumor 
cell-derived CCL2 promotes macrophage recruitment both in vitro and in vivo [189-191]. 
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In recent studies, both CCL2 and CCL5/RANTES were found to correlate with increased 
macrophage recruitment in human patient samples, and specifically in ER+ samples [192]. 
Using estrogen-supplemented oophorectomized mice bearing MMTV-PyMT mammary 
tumors, further studies demonstrated that inhibition of either CCL2 or CCL5 using 
blocking antibodies resulted in reduced macrophage infiltration and reduced tumor 
growth [192]. In addition to promoting recruitment of macrophages to the primary tumor 
site, CCL2 has also been implicated in indirectly promoting the seeding and growth of 
tumor cells in the metastatic site. Specifically, CCL2 was found to recruit a distinct 
population of macrophages termed metastasis-associated macrophages, defined as 
CD11b+ / Ly6Chigh, to the lung metastatic site [124]. Once localized to this site, CCR2 
activation stimulates macrophages to secrete an additional chemokine, CCL3, which 
contributes to tumor cell-macrophage interactions and retention in the metastatic site 
through activation of CCR1 [193]. Taken together, these studies suggest that blocking 
macrophage recruitment through inhibition of chemokine signaling may effectively 
reduce macrophage contributions during tumor growth and progression. However, some 
challenges have been associated with targeting chemokines including the induction of 
compensatory mechanisms in response to chemokine inhibition. In a recent study 
evaluating CCL2 blockade, Bonapace et al. found that while blocking CCL2 reduced 
lung metastasis, which was maintained upon continuous CCL2 inhibition, cessation of 
CCL2 neutralization led to increased metastasis and accelerated death [194]. Assessment 
of combinatorial therapies, which included targeting additional cytokines, such as IL-6, 
that were increased in the lungs upon treatment cessation, alleviated the increase in 
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metastasis. Thus, these studies suggest that targeting chemokines, such as CCL2, as a 
therapeutic strategy should be approached with caution and could possibly require 
combination-based approaches for success. 
 
In addition to CSF-1 and CCL2, other chemokines have also been linked to 
macrophage recruitment in the primary tumor site. Using an inducible model of 
mammary tumorigenesis, we identified CX3CL1 as a mediator of macrophage 
recruitment to early stage mammary hyperplasias [66]. More recent studies have linked 
CX3CL1 expression with poor outcome in breast cancer patients [195], although whether 
high CX3CL1 is linked to macrophage recruitment in human breast cancer samples 
remains to be determined. Boyle et al. recently reported that CCL20-CCR6 axis is 
important for regulating macrophage recruitment into mammary tumors of MMTV-
PyMT mice [196]. In these studies, growth of mammary tumors in CCR6-knockout mice 
led to reduced mammary tumor initiation and growth. Further analysis of these tumors 
revealed a reduction in immune cell infiltration along with changes in macrophage 
polarization as shown by reduced expression of IL-4R and CD206. Importantly, 
reconstitution of TAMs into CCR6-knockout mice bearing orthotopically transplanted 
MMTV-PyMT tumors restored tumor growth demonstrating the importance of this 
chemokine axis for mammary tumor growth. In addition to general recruitment to the 
tumor microenvironment, a subpopulation of macrophages is also known to accumulate 
in hypoxic regions within tumors. Recruitment of macrophages into hypoxic regions is 
mediated through soluble factors such as VEGF, endothelin-2, and angiopoietin-2 
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[197,198]. Semaphorins, such as SEMA3A, were recently linked to recruitment of 
macrophages to hypoxic regions via a neuropilin-1-dependent mechanism [199]. 
Additional recent studies have also found that hypoxic cancer cells produce 
chemoattractants that promote macrophage recruitment, including oncostatin M and 
eotaxin, which also act to polarize macrophages to a pro-tumor phenotype and are 
required for tumor progression [200]. Taken together, these studies demonstrate that 
macrophage recruitment into the tumor microenvironment can be driven by many 
different factors, highlighting the complexity of the mechanisms driving macrophage 
infiltration. 
 
Although less extensively studied compared with tumor cell-derived chemokines, 
stromal cells, including carcinoma associated fibroblasts (CAFs), mesenchymal stem 
cells (MSCs), and endothelial cells, also produce chemokines that can potentially recruit 
macrophages into the microenvironment. Stimulation of CAFs and MSCs with tumor 
cell-derived conditioned media leads to upregulation of various chemokines, including 
CCL2, CXCL8, and CCL5 [201]. Furthermore, Yoshimura et al. demonstrated that 
stromal cell-derived CCL2 contributes to macrophage recruitment to 4T1 tumors and that 
loss of stromal cell CCL2 leads to decreased lung metastasis [202]. Recent genetic 
studies have demonstrated a critical role for BMP signaling in the regulation of 
chemokines from fibroblasts. Specifically, loss of BMPR2 from fibroblasts led to 
increased metastasis of MMTV-PyMT tumors corresponding with increased chemokine 
expression and increased infiltration of myeloid cells [203]. 
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In addition to chemoattractants derived from tumor and stromal cells, there is 
evidence that tumor-associated ECM may also contribute to macrophage recruitment. For 
example, collagen fragments are known to be chemotactic for inflammatory cells [204]. 
Furthermore, it has been proposed that proteolysis of collagen I promotes macrophage 
recruitment into the involuting mammary gland, which is characterized as a tumor-
promoting environment [205]. Another ECM component linked to macrophage 
recruitment is hyaluronan, which is a glycosaminoglycan consisting of repeating 
disaccharide subunits of glucuronic acid and N-acetylglucosamine. Macrophages are 
often associated with a hyaluronan-containing matrix within the tumor environment, and 
studies have suggested that hyaluronan can act directly on macrophages to regulate their 
migration [206]. Specifically, hyaluronan has been shown to promote macrophage 
chemotaxis using in vitro chemotaxis assays [207]. Consistent with these findings, in 
vivo studies have demonstrated that reduction of hyaluronan in the mammary tumor 
stroma correlates with decreased macrophage infiltration [208]. Taken together, the 
numerous studies focusing on macrophage recruitment demonstrate that macrophage 
infiltration into the tumor microenvironment can potentially be mediated by a variety of 
factors (Figure 1.4). Further studies are warranted to understand the relative contributions 
of tumor cell versus stromal cell derived chemokines and ECM components to 
macrophage recruitment during tumor growth and progression. 
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Figure 1.4. Complex interactions in the tumor microenvironment 
Breast cancer cells located in the tumor periphery (red rectangles) secrete cytokines and chemokines, which recruit 
monocytes from the circulation and differentiate them into tumor-associated macrophages (TAMs). Tumor cells 
located in the inner, hypoxic region (blue rectangles) develop a more specialized array of molecules to recruit 
macrophages poised to help the hypoxic cells survive and proliferate. The stromal cells of the tumor, along with 
components of the extracellular matrix (such as collagen I and hyaluronan), additionally contribute to the 
recruitment and retention of TAMs. Once educated by the tumor microenvironment, TAMs upregulate pathways 
associated with both M1- and M2-activated macrophages and actively support the survival, proliferation, and 
metastasis of breast cancer cells. 
  45 
Macrophage Polarization in the Tumor Microenvironment 
Once recruited to the tumor microenvironment, macrophages respond to the 
plethora of stimuli within the microenvironment and differentiate into various effector 
subsets. Numerous studies have focused on defining macrophage subsets within the 
tumor microenvironment. Currently, the most widely accepted classification of 
macrophage polarization is based on descriptions of classical (M1) versus alternative 
(M2) polarization, which were developed as a result of initial studies investigating 
macrophage responses to helper T cells 1 (Th1) and helper T cell 2 (Th2) derived 
molecules [209]. Classically activated macrophages develop in response to interferon-
gamma (IFNγ) and pathogen-derived toll-like receptor ligands [133,210]. This response 
is characterized by the production of cytotoxic factors such as reactive oxygen species 
and nitric oxide, increased rates of phagocytosis, and enhanced antigen presentation on 
the cell surface. Alternatively activated macrophages, on the other hand, develop as part 
of the wound healing program and as such are thought to antagonize inflammation. M2 
macrophages are induced by the Th2 cytokines IL-4 and IL-13, as well as in response to 
IL-10, immunoglobulins, and glucocorticoids [150,211]. These cells, in turn, secrete 
factors that promote angiogenesis, upregulate expression of scavenging receptors, and 
produce enzymes to remodel the surrounding extracellular matrix. As interest and work 
in the field of macrophage biology has expanded, the nomenclature describing the 
activation status of macrophages has become complex and often confusing. In an attempt 
to streamline the methods used to generate and describe the cells used by the different 
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research groups, Murray et al. published a comprehensive set of recommendations which 
will undoubtedly simplify future analysis and comparison of macrophage subsets [212]. 
 
Based on their functions within the tumor microenvironment, TAMs have been 
generally characterized as M2-like [150]. Several studies have demonstrated that TAMs 
express higher levels of scavenging receptors, angiogenic factors, and proteases, similar 
to M2 macrophages. Furthermore, TAM polarization to the M2-like phenotype in the 
MMTV-PyMT model has been attributed to IL-4-producing Th2 cells within the tumor 
microenvironment [183]. However, there is evidence that macrophages exhibit different 
phenotypes during different stages of tumor initiation and progression. During early 
stages of transformation, recently recruited macrophages are exposed to a wide variety of 
pro-inflammatory signals derived from the epithelial cells and the surrounding stroma 
and often express M1-related factors that have pro-tumorigenic properties, such as IL-
1β and IL-6 [213,214]. As a component of the pro-inflammatory response, production of 
reactive oxygen and nitrogen species could also potentially enhance the rate of epithelial 
cell mutation and thus accelerate tumorigenesis [215]. In established tumors, 
macrophages exhibit alternatively activated functions including the production of 
immunosuppressive factors, such as IL-10 and TGF-β, which are capable of actively 
suppressing the antitumor immune response [174,182,183]. These macrophages also 
produce growth factors and remodel the matrix, supporting tumor cell growth and 
enhancing invasion. Therefore, TAM phenotypes are now thought to include a 
combination of markers typically assigned to the M1 and M2 phenotypes. Thus, as efforts 
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are being made to “repolarize” macrophages within the tumor microenvironment towards 
the M1/classically activated phenotype, care must be taken to ensure that the potentially 
pro-tumorigenic functions of these macrophages are suppressed. 
 
Recent sophisticated analyses utilizing genome-wide studies and RNA-
sequencing have revealed that macrophage phenotypes in vivo are far more 
heterogeneous and complex than initially expected. Xue et al. performed a detailed 
transcriptome analysis of primary human monocytes stimulated with 28 different signals, 
the results of which suggest a “spectrum” model where 9 different macrophage activation 
programs were identified in response to different combinations of stimuli [216]. Analysis 
of the enriched gene sets in human macrophages derived from smokers and COPD 
patients revealed activation programs within these primary macrophages that were 
significantly different from the hypothesized phenotypes. In smokers' samples, a complex 
network of stimuli including glucocorticoids, free fatty acids, and IL-4 were detected, 
while in COPD patient samples the previously published IL-4/IL-13 associated gene 
signatures were not reproduced and instead a profound loss of inflammatory genes was 
reported [216]. These results demonstrate the complexity of activating signals responsible 
for the phenotypes of macrophages in human pathologies, and they suggest that a simple 
bipolar M1/M2 paradigm may not be sufficient to describe macrophages associated with 
disease states. Based on the observation that the microenvironment of lung disease is 
capable of producing a spectrum of macrophage activation states, it seems likely that this 
heterogeneity would also be observed in the tumor microenvironment. Indeed, while 
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performing gene-expression profiling on TAMs and mammary tissue macrophages from 
tumor bearing MMTV-PyMT mice, Franklin et al. observed few canonical M2 markers 
to be upregulated in the TAM population [186]. Instead, they reported TAM 
differentiation to be dependent on signaling of the transcription factor Rbpj, a key 
regulator of canonical Notch signaling. 
 
In addition, recent evidence suggests that individual tumors may contain several 
different subsets of macrophages and those might differ in their functions. Movahedi et 
al. reported the presence of two distinct TAM populations in mammary TS/A tumors, 
distinguishable most easily by the level of MHCII expression on their surface [217]. 
MHCIIlo macrophages were shown to reside mainly in hypoxic tumor regions and 
expressed markers associated with M2 polarization. The MHCIIhi subset, however, 
expressed M1-signature genes such as Ptgs2 (COX-2), Nos2, and Il12. These cells were 
shown to secrete pro-inflammatory cytokines and chemokines such as IL-6, CCL5, and 
CXCL3, which could in turn serve to further recruit additional pro-inflammatory cells to 
the tumor margins. However, both macrophage subsets were shown to be poor antigen 
presenting cells and were able to suppress T cell proliferation, indicating that both subsets 
might be capable of contributing to pro-tumor immunosuppression. Interestingly, Ruffell 
et al. observed a similar localization of MHCIIlo and MHCIIhi TAMs in mammary tumors 
derived from MMTV-PyMT mice; however, the ability of TAMs to suppress CD8+ T cell 
proliferation was limited to the MHCIIlo subset of cells [182]. These findings indicate that 
some TAM properties are most likely universal (recruitment, localization), whereas other 
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properties (specific interactions with other infiltrating cells) might be dependent on the 
tumor model under investigation. In a recent study examining macrophage localization 
within human breast tumors, high CD68+ macrophage staining within gaps of ductal 
tumor structures correlated with reduced lymph node metastasis [218]. Taken together, 
these data suggest that TAMs represent a macrophage population that is distinct from 
both M1 and M2 macrophages as they are canonically described in the setting of 
infection, but there is most likely a spectrum of TAMs whose phenotype and function 
depend on tumor type and location within the tumor. 
 
 While the soluble factors produced by macrophages which modulate the 
microenvironment have been extensively characterized, the transcription factors that 
regulate macrophage function remain understudied. Macrophages respond to numerous 
cytokines found in the microenvironment, many of which signal through the Janus kinase 
/ signal transducer and activator of transcription (JAK/STAT) signaling pathway. Many 
members of this family, such as STAT1 and STAT3, have known regulatory functions in 
macrophages. However, relatively little is known about the role of a related family 
member, STAT5, in regulating macrophage function. Interestingly, STAT5 was 
originally identified in mammary epithelial cells as the gene named mammary gland 
factor (MGF) where it was shown to regulate the expression of key milk protein genes 
during lactation [219,220]. STAT5 has also been shown to play an important role in the 
proliferation, differentiation and survival of mammary epithelial cells [95,96,221-224].  
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In addition to the well-characterized role of STAT5 in epithelial cells, much is 
known about the function of STAT5 in several different immune cell subsets. Proper T 
cell activation and survival requires STAT5 as a major downstream transcriptional 
effector of IL-2 signaling [225]. Studies from STAT5-deficient mice have revealed a 
block in lymphocyte development and demonstrated a role for STAT5 in regulating the 
lineage commitment between CD4+ and CD8+ T cells [226,227]. In DCs, STAT5 
signaling has been implicated as an important regulator of polarization, where STAT5-
deficient DCs fail to promote TH2 responses in T cells while TH1 responses are 
unaffected [228]. These studies illustrate that STAT5 signaling regulates specific immune 
responses and can modulate the interface between innate and adaptive immunity. 
 
Very little is known about the effects of STAT5 signaling in macrophages on the 
regulation of immune responses and less is known about its role in tissue-resident 
macrophages during development. Previous studies have suggested that STAT5 may 
contribute to macrophage polarization downstream of IL-3 [229], but no studies have 
directly explored the function of STAT5 signaling in macrophages during normal 
mammary gland development or tumorigenesis. 
 
Thesis Statement 
The overarching hypothesis of this dissertation is that STAT5 is a critical 
regulator of macrophage function, both in tissue-resident macrophages during mammary 
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gland development and tumor-associated macrophages during breast cancer growth and 
progression. The specific goals of the studies in the following chapters are as follows:  
• Characterize how STAT5 in macrophages regulates normal mammary 
gland development. 
• Define the role of STAT5 in macrophages during mammary tumorigenesis 
• Determine the implications of modulating STAT signaling as a therapeutic 
intervention. 
The successful completion of these studies will provide insight into the mechanism by 
which macrophages regulate mammary gland development, provide critical data 
highlighting the role of STAT5 signaling in TAMs, and reveal novel therapeutic targets 
to pursue in combination with JAK/STAT inhibitors that are currently in clinical trials 
(Figure 1.5). 
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Chapter 2. STAT5 Deletion in Macrophages Alters Ductal Elongation 
and Branching During Mammary Gland Development 
 
Introduction 
Recent efforts have emphasized the importance of tissue resident macrophages in 
regulating tissue homeostasis [230]. Resident macrophages are subject to tissue 
programming and these macrophages exhibit distinct functions based on the tissue in 
which they reside and their localization within the tissue [231]. Macrophages have been 
documented in the mammary gland and have been linked to regulating the formation of 
epithelial structures during mammary gland development [140,144-146,232]. However, 
the specific mechanisms that drive macrophage function within the mammary gland have 
not been fully elucidated. 
 
Elongation of the mammary ducts during puberty, which is driven by specialized 
structures at the tip of the ducts called terminal end buds [90-92], requires a complex set 
of reciprocal interactions between epithelial cells and the surrounding stroma. Numerous 
different cell types, including innate and adaptive immune cells, contribute to signaling in 
the microenvironment through the production of cytokines, chemokines, growth factors, 
and extracellular matrix components [87,138,139,145,233,234]. Macrophages are found 
in close association with the epithelium during all stages of mammary gland 
development, suggesting the existence of a paracrine signaling network between the two 
cell types [138-140]. Previous work has shown that macrophages are essential for the 
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ductal elongation and side-branching that normally occur during puberty [140,144]. 
While the factors that recruit macrophages to the developing epithelial structures have 
been characterized, the signaling pathways that are activated in the recruited 
macrophages as well as the mediators produced by macrophages that regulate mammary 
gland development remain understudied. Mammary gland development is tightly 
regulated by a combination of circulating and locally derived factors, including 
hormones, growth factors and cytokines. The majority of studies have focused on the 
effects of these factors specifically on mammary epithelial cells. However, it is feasible 
these factors also activate signaling pathways in macrophages that contribute to their 
programming and function. 
 
In many instances during tumor development, cancer cells exploit existing 
developmental processes to promote their own growth [235]. These processes, which in 
some cases have been dormant for decades, are reactivated to provide growth factors and 
stimuli not typically produced in the normal environment. Thus, understanding the 
process of normal mammary gland development will provide valuable mechanistic 
insight into tumor initiation and progression. In addition to being found in the mammary 
gland during normal development, macrophages are often found embedded within 
developing tumors. These tumor-associated macrophages (TAMs) regulate many 
processes that are critical for tumorigenesis, such as tumor cell invasion, migration, and 
proliferation [55,67,178,236]. Clinically, increased numbers of infiltrating TAMs are 
correlated with poor patient prognosis in numerous cancer types, including breast cancer 
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[170,171,237,238]. Thus, understanding the signaling pathways that control how 
macrophages respond to and promote tumor initiation and progression is critical for the 
development of novel therapeutic strategies. 
 
The studies described here focus on identifying key signaling pathways that 
regulate macrophage function during ductal elongation in the mammary gland. Signal 
transducer and activator of transcription 5 (STAT5) is one signaling pathway that has 
been previously implicated in mammary epithelial cell proliferation, differentiation and 
survival [95,96,221-224]. In this work, we identify a novel function of STAT5 as a 
regulator of macrophage function during mammary gland development and demonstrate 
that STAT5 is normally activated in a subset of mammary gland macrophages during 
development. We use a conditional knockout of STAT5 to demonstrate that the loss of 
STAT5 in macrophages results in altered mammary gland development that is consistent 
with increased estrogen production and signaling. Our studies also demonstrate that 
STAT5 deletion in macrophages enhances the formation of ER-positive epithelial lesions 
in an inducible hyperplasia model. Finally, we demonstrate that treatment of 
macrophages with inflammatory cytokines results in altered STAT5 binding to target 
sites in the Cyp19a1 locus, suggesting that exposure to an inflammatory milieu, either 
local or systemic, could alter the ability of resident macrophages in the mammary gland 
to maintain homeostasis. The results from these studies describe a novel mechanism of 
regulation of macrophages in the mammary gland and demonstrate that alterations in 
signaling pathways in these macrophages are capable of contributing to the development 
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of tissue-specific disease. Understanding the specific mechanisms through which 
macrophages within the mammary gland maintain homeostasis will ultimately lead to the 
development of approaches that can be used to manipulate their functions for prevention 
and/or therapeutic purposes. 
 
Materials and Methods 
Mice. Csf1r-iCre mice were provided by Dr. Elaine Lin [239] on the FVB background 
and Stat5fl/fl mice were provided by Dr. Lothar Hennighausen [95]. Wild-type FVB mice 
were purchased from Harlan Laboratories and the Stat5fl/fl mice were backcrossed to the 
FVB/N background and backcrossing was verified using congenic analysis (IDEXX-
RADIL, Columbia, MO). Daily estrous staging was performed as previously described 
using crystal violet-stained cytology of vaginal lavage fluid [240]. Two hours prior to 
sacrifice, mice were injected with 30 mg/kg BrdU by intraperitoneal injection. All animal 
care and procedures were approved by the Institutional Animal Care and Use Committee 
of the University of Minnesota and were in accordance with the procedures detailed in 
the Guide for Care and Use of Laboratory Animals. 
 
Immunoblot analysis. Protein lysates were subjected to SDS-PAGE using 20 µg total 
protein. Immunoblot analysis was performed using antibodies listed in the Appendix. 
 
Immunohistochemistry and immunofluorescence. Mammary glands were harvested, 
fixed in 4% paraformaldehyde for 2 hours, sectioned and stained as previously described 
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[55] using conditions listed in the Appendix. All images were acquired using Leica LAS 
software. 
 
Cell culture: HC-11 cells were maintained as previously described [60,241]. RAW264.7 
cells were grown in media containing DMEM (Life Technologies) supplemented with 
10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (Life Technologies). Bone 
marrow was flushed from the femurs and tibiae of mice and plated overnight in DMEM + 
10% FBS. Non-adherent cells were collected and re-plated in low-attachment plates with 
DMEM + 10% FBS + 20% conditioned media from L929 cells, a cell line that produces 
high levels of macrophage-colony stimulating factor. Differentiated macrophages were 
subsequently re-plated in normal tissue culture dishes for experiments. 
 
qRT-PCR. Cells were cultured as described above, RNA harvested using TriPure 
Reagent (Roche) and quantitative reverse transcription PCR was done as previously 
described [67] using qScript cDNA SuperMix and PerfeCTa SYBR Green SuperMix 
(Quantabio). Gene expression was normalized to Ppib (cyclophilin B) levels. Primer 
sequences used are listed in the Appendix. 
 
Mammary gland whole mounts. Mammary glands were harvested and fixed in 4% 
paraformaldehyde for 2 hours, rinsed in 70% ethanol and stained in Carmine alum 
overnight. Glands were dehydrated using 70%, 95%, and 100% ethanol then cleared in 
xylene. Stained glands were imaged and subsequently stored in methyl salicylate.  
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Chromatin Immunoprecipitation (ChIP). RAW264.7 macrophages were plated at 
3x106 cells per plate in a 10cm plate in DMEM + 10% FBS overnight. Cells were 
subsequently washed and serum-starved in DMEM overnight and fixed or treated with 50 
ng/mL IL-6 as indicated before being fixed. Primary BMDMs were plated at 5x105 cells 
per 6cm plate and grown for 48 hours. Cells were subsequently washed and serum-
starved in DMEM for 4 hours and fixed or treated with 50 ng/mL IL-6 as indicated before 
being fixed. ChIP was performed with a STAT5-specific antibody (sc-836X, Santa Cruz), 
STAT3-specific antibody (sc-482X, Santa Cruz) or non-specific rabbit IgG isotype 
control using Protein G magnetic beads (Active Motif). Analysis was performed using 
methods as previously described [242]. All ChIP data presented are normalized to % 
input chromatin and presented as fold enrichment over IgG control. Primers sequences 
are listed in the Appendix. 
 
Microarray analysis. Microarray expression analysis was performed as previously 
described [66]. Female FVB mice were sacrificed at 6 weeks or 10 weeks of age and 
mammary glands were collected for analysis. Tissue was dissociated with 2 mg/mL 
collagenase A (Roche) for 45 minutes at 37°C with gentle rocking. The solutions were 
vigorously shaken every 15 minutes and the cells were collected by centrifugation at 
1500 rpm for 5 minutes. The cells were washed 3 times in DMEM/F-12 with 5% FBS 
and centrifuged at 1500 rpm for 5 minutes followed by 2 times at 800 rpm for 5 minutes. 
The cells were stained with CD11b-APC (Life Technologies) at a dilution of 1:200 or 
isotype control for 1 hour at room temperature. The cells were then subsequently washed, 
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filtered through a 40 µm filter and sorted with a triple laser MoFlo (Cytomation). RNA 
was isolated from CD11b+ cells sorted from 6 mice per timepoint and pooled into 
duplicate samples. RNA was extracted using the Arcturus PicoPure RNA Isolation Kit 
(Life Technologies) and hybridized to the Affymetrix MOE 2.0 microarray (Affymetrix) 
in the Baylor Microarray Core Facility at Baylor College of Medicine (Houston, TX). 
Raw data were normalized using Microarray Suite 5.0 and genes called absent in all 
samples were discarded, while genes that were either upregulated or downregulated at 
least 2-fold with a p-value of less than 0.05 were further analyzed. Data have been 
deposited in the National Center for Biotechnology Information Gene Expression 
Omnibus data repository, accession number GSE36477. 
 
Fluorescence-activated cell sorting (FACS). Both #3 and both #4 mammary glands 
were harvested from 6-week-old female mice. Tissue was minced with scalpels and 
subsequently digested in 2 mg/mL collagenase A for 1 hour at 37°C. Cells were pelleted 
by centrifugation and stained for FACS with antibodies listed in Supplemental Table 1. 
Cell sorting was performed using a BD FACSAria II at the University Flow Cytometry 
Resource of the University of Minnesota. Sorted cells were processed for qRT-PCR as 
described above.  
 
Statistical analysis. Statistical analysis was performed using Student’s unpaired, two-
tailed t-test. Comparisons between multiple groups was performed using one-way 
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ANOVA with Tukey’s multiple comparison test. Error bars represent standard error of 
the mean (SEM). 
 
Results 
STAT5 is activated in macrophages in the mammary gland  
Numerous local and endocrine factors that are critical for mammary gland 
development potentiate downstream signaling through STAT proteins, including growth 
hormone, prolactin, and cytokines such as interleukin-4 (IL-4) and IL-13 [96,98]. These 
factors are capable of acting on both epithelial cells and stromal cells, and thus we 
reasoned that in addition to activation in mammary epithelial cells, STATs may also be 
activated in cells located within the stroma, such as macrophages, and contribute to their 
tissue-specific function. Additionally, it has been previously shown that the expression of 
transcription factors in tissue-resident macrophages is controlled by factors found in the 
local microenvironment [243,244]. Thus, we initially examined the expression of STAT 
family members due to their known contributions to mammary gland development. To 
determine whether STAT proteins are differentially expressed in macrophages derived 
from different tissues, gene expression of STAT family members was assessed from 
intraperitoneal or mammary gland macrophages from 6-week- and 10-week-old mice. 
Expression levels of Stat5a were significantly higher in mammary gland-derived 
macrophages isolated from both 6-week and 10-week-old mice compared with peritoneal 
macrophages (Figure 2.1). STAT5 is a transcription factor that has been well-studied as a 
key regulator of milk protein gene expression in mammary epithelial cells and is also a  
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Figure 2.1. STAT5 expression is enriched in mammary gland macrophages 
Microarray gene expression from intraperitoneal (IP) or mammary gland (MG) macrophages. * p<0.05, **** 
p<0.0001. 
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critical regulator of mammary epithelial cell proliferation, differentiation, and survival 
[95,96,221-224]. STAT5 regulates various functions in a variety of immune cell subsets. 
In B and T cells, STAT5 is an essential regulator of development and differentiation 
[226], while in dendritic cells STAT5 is critical for promoting a TH2 response [228]. 
Previous work has suggested that STAT5 may be involved in regulating IL-3-mediated 
polarization [229], however, little else is known about the role of STAT5 in 
macrophages. 
 
Initial studies were performed to examine the activation status of STAT5 in 
stromal cells in vivo. Paraffin-embedded mammary glands from pubertal wild-type mice 
were stained for p-STAT5, revealing numerous p-STAT5+ cells located both within and 
surrounding mammary ducts (Figure 2.2). To determine the identity of these cells, tissue 
sections were co-stained for p-STAT5 and the epithelial marker keratin 8 (K8). While 
some p-STAT5+ / K8+ epithelial cells were observed, as expected, we also observed 
activation of STAT5 in a number of stromal cells, including a large population of p-
STAT5+ / K8- cells found in close proximity to the epithelium (Figure 2.3). These cells 
were located in a region around the terminal end buds where macrophages have been 
shown to reside [138,139]. To determine whether macrophages represent a population of 
p-STAT5+ / K8- cells, cryosectioned mammary glands from wild-type mice were co-
stained for p-STAT5 and F4/80. Numerous F4/80+ cells were observed along the neck of 
the terminal end bud with 30% of these cells also being p-STAT5+, demonstrating 
activation of STAT5 in a subset of mammary gland macrophages in vivo (Figure 2.4).  
  63 
  
Figure 2.2. STAT5 activation in mammary stroma 
Paraffin-embedded mammary gland sections stained for p-STAT5 and counterstained with hematoxylin. Region 
identified in square magnified to the right and arrowhead indicates a p-STAT5+ stromal cell. Scale bar represents 
50 µm. 
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Figure 2.3. Activation of STAT5 in the mammary gland 
Paraffin-embedded mammary gland sections were stained for K8 (red), p-STAT5 (green), and DAPI (blue). Region 
identified in square magnified to the right. Scale bar represents 50 µm. 
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Figure 2.4. STAT5 is activated in mammary gland macrophages 
  
Frozen mammary gland sections were stained for F4/80 (red), p-STAT5 (green), and DAPI (blue). Arrowheads 
indicate p-STAT5+ macrophages and region identified in square magnified to the right. Scale bar represents 50 µm. 
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To determine the role of STAT5 signaling in macrophages during mammary 
gland development, a conditional knock-out approach was taken to generate mice 
carrying a tissue-restricted deletion of STAT5. These mice have both the Stat5a and 
Stat5b loci flanked by loxP recombination sites (STAT5fl/fl) and were crossed to mice 
harboring a transgene expressing Cre recombinase under the control of the Csf1r 
promoter (STAT5ΔMϕ), which deletes predominantly in myeloid cells [239]. Deletion of 
STAT5 was verified in primary bone marrow-derived macrophages (BMDMs) by 
quantitative reverse transcription PCR (qRT-PCR) (Figure 2.5A) and immunoblot 
analysis (Figure 2.5B). To further confirm the deletion of STAT5, mammary glands from 
STAT5fl/fl and STAT5ΔMϕ mice were harvested and subjected to fluorescence-activated 
cell sorting. Populations of CD45+ ; F4/80+ cells, representing mammary gland 
macrophages, were collected and transcript levels of both Stat5a and Stat5b were found 
to be reduced in mammary gland macrophages from the STAT5ΔMϕ mice compared to 
littermate STAT5fl/fl control mice (Figure 2.5C). The expression of Cre is limited 
primarily to myeloid cells and no deletion of STAT5 was detected in mammary epithelial 
cells (Figure 2.6). 
 
STAT5 deletion in macrophages disrupts normal mammary gland development 
To assess STAT5 function in macrophages within the mammary gland, mammary 
gland development was analyzed in STAT5fl/fl and STAT5ΔMϕ mice. To account for 
morphological changes that occur during the estrous cycle, 6-week-old STAT5fl/fl and  
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Figure 2.5. Deletion of STAT5 in macrophages 
  
A) Expression of Stat5a and Stat5b assessed by qRT-PCR in BMDMs from STAT5fl/fl and STAT5ΔMϕ mice. B) 
Immunoblot of STAT5 levels in BMDMs from STAT5fl/fl and STAT5ΔMϕ mice. GAPDH is shown as a loading 
control. C) Expression of Stat5a and Stat5b assessed by qRT-PCR in sorted mammary gland macrophages from 
STAT5fl/fl and STAT5ΔMϕ mice. * p<0.05, *** p<0.001. 
A 
B 
C 
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Figure 2.6. STAT5 is not deleted in MECs 
Immunohistochemical staining of mammary glands from STAT5fl/fl and STAT5ΔMϕ mice. Sections were stained for 
STAT5 and counterstained with hematoxylin. Regions identified in squares magnified in insets. Scale bars 
represent 50 µm. 
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STAT5ΔMϕ mice were staged as previously described [240] and mammary glands were 
harvested during diestrus. Whole mount analysis revealed no differences in terminal end 
bud number in mammary glands from STAT5fl/fl and STAT5ΔMϕ mice (Figure 2.7A). 
However, a significant reduction in ductal elongation (Figure 2.7B) and a significant 
increase in lateral branchpoints per duct (Figure 2.7C) were observed in mammary glands 
from STAT5ΔMϕ mice compared to littermate controls. Deletion of the related 
transcription factor STAT3 in macrophages did not result in any gross developmental 
perturbations (data not shown). As an additional control, mammary glands from 
STAT5fl/+ ; Csf1r-iCre+ mice which carry a heterozygous deletion of STAT5 in cells of 
the myeloid lineage (STAT5fl/Δ) exhibited no defect in ductal elongation (Figure 2.8), 
suggesting that the observed changes in mammary gland development are specifically 
attributable to the loss of STAT5 in macrophages and not due to non-specific effects of 
Cre recombinase expression. 
 
To determine if the observed changes in mammary gland development were 
accompanied by architectural changes in the ductal structure, mammary glands from 
STAT5fl/fl and STAT5ΔMϕ mice were stained for K8 and keratin 14 (K14). Mammary 
glands from both genotypes showed normal ductal architecture, with a single layer of K8+ 
luminal cells surrounded by a single layer of K14+ myoepithelial cells, and no gross 
architectural abnormalities were noted by hematoxylin and eosin (H&E) staining (Figure 
2.9). F4/80 staining demonstrated that there were no differences in macrophage 
recruitment to epithelial structures between mammary glands from STAT5fl/fl or  
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A B 
C 
Figure 2.7. Deletion of STAT5 in macrophages disrupts ductal morphogenesis 
A) [Top] Whole mount analysis of mammary glands. [Middle] High-power magnification of mammary ducts. 
[Bottom] High-power magnification of terminal end buds. B) Quantification of ductal elongation in mouse 
mammary glands. C) Analysis of epithelial branch points per mammary duct. Scale bars represent 1 mm. **p<0.01. 
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B A 
Figure 2.8. Phenotype of STAT5ΔMϕ mice is not due to Cre expression 
A) Mammary gland whole mount from a STAT5fl/+ ; c-fms Cre+ (STAT5Δ/+) mouse. B) Ductal displacement in 
mammary glands from STAT5fl/fl, STAT5Δ/+, and STAT5ΔMϕ mice. Scale bar represents 1 mm. *p<0.05, 
***p<0.001. 
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STAT5ΔMϕ mice (Figure 2.9). To address whether the decreased ductal elongation and 
increased side branching were associated with altered rates of proliferation, BrdU 
incorporation was assessed by immunofluorescence. Mammary glands from the 
STAT5ΔMϕ mice showed a significant increase in the number of proliferating cells 
compared to those from STAT5fl/fl control mice (Figure 2.10A). The increased 
proliferation is specific to established mammary ducts, as proliferation was found to be 
equivalent in the highly proliferative terminal end bud in mammary glands from 
STAT5fl/fl and STAT5ΔMϕ mice (Figure 2.10B). Additionally, analysis of mammary gland 
whole mounts from 10-week-old STAT5ΔMϕ mice indicates that ductal elongation 
recovers and is similar to control mice at that timepoint (Figure 2.11). These data 
demonstrate that the loss of STAT5 signaling in macrophages impairs normal ductal 
development and promotes proliferation in the mammary gland. 
 
Increased expression of ER targets in mammary glands from STAT5ΔMϕ mice  
Normal mammary gland development is tightly regulated by hormone signaling 
and any perturbations in hormone levels result in altered mammary gland morphology 
[99,245,246]. Administration of exogenous estrogens to mice results in decreased ductal 
elongation and increased epithelial branching [104], similar to the observed phenotype in 
STAT5ΔMϕ mice.  Therefore, experiments were performed to determine whether estrogen 
signaling was enhanced in mammary glands from STAT5ΔMϕ mice. To investigate the 
contributions of hormone signaling, six-week-old STAT5fl/fl and STAT5ΔMϕ mice were 
staged in their estrous cycles, inguinal mammary glands were harvested during diestrus   
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Figure 2.10. Proliferation is specifically increased in mature mammary ducts of STAT5ΔMϕ mice 
  
A 
B 
A) [Left] Immunofluorescent staining of mature mammary ducts from STAT5fl/fl and STAT5ΔMϕ mice. Sections 
were stained for BrdU (red) to assess proliferation and counterstained with DAPI (blue).Regions identified in 
squares magnified in inset. [Right] Quantification of proliferating cells normalized to total number of DAPI+ cells. 
B) Immunofluorescent staining of terminal end buds from STAT5fl/fl and STAT5ΔMϕ mice. Sections were stained 
for BrdU (red) to assess proliferation and counterstained with DAPI (blue). Scale bars represent 50 µm. 
****p<0.0001. 
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Figure 2.11. Ductal elongation in STAT5ΔMϕ mice matches STAT5fl/fl mice at 10 weeks of age 
Mammary gland whole mounts from 10-week-old, estrous-staged STAT5fl/fl and STAT5ΔMϕ mice. Scale bars 
represent 1 mm. 
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and mammary epithelial cells were harvested following collagenase digestion. 
Assessment of the canonical ER targets Ctsd, Wnt4 and AREG demonstrated increased 
expression in mammary epithelial cells from STAT5ΔMϕ mice compared to littermate 
controls (Figure 2.12A-C). No alterations were observed in the quantity or distribution of 
ER+ mammary epithelial cells between STAT5fl/fl and STAT5ΔMϕ mice (Figure 2.13) 
suggesting that increased ER target gene expression was not due to increased numbers of 
ER+ epithelial cells. Additionally, no differences in estrous cycle stages or length were 
observed between STAT5fl/fl and STAT5ΔMϕ mice, suggesting that the loss of STAT5 in 
macrophages does not affect global hormone signaling homeostasis (Figure 2.14).  
 
Increased aromatase expression in STAT5-deficient macrophages 
While we observed an increase in estrogen signaling in the mammary glands of 
STAT5ΔMϕ mice, we did not find significantly elevated levels of circulating estrogen 
(Figure 2.15). Thus, a potential mechanism to explain the increased ER target gene 
expression observed in the STAT5ΔMϕ mice is an increased local production of estrogen. 
Aromatase, the protein product of the cytochrome P450, family 19, subfamily A, 
polypeptide 1 (Cyp19a1) gene, is a critical enzyme required for the biosynthesis of 
estrogen. STAT5 has been previously implicated in repression of gene expression 
through tetramerization and binding to tandem consensus sequences in the genome 
[247,248]. A putative STAT5 tetramer binding site was identified in the large first intron 
of the Cyp19a1 gene, approximately 700bp downstream of the transcription start site 
(Figure 2.16). To model the mammary gland microenvironment in vitro, primary  
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Figure 2.12. Increased expression of ER targets in mammary glands from STAT5ΔMϕ mice 
  
A 
B
 
C
 
A) qRT-PCR for ER target genes in mammary epithelial cells isolated from STAT5fl/fl and STAT5ΔMϕ mice. B) 
Paraffin-embedded mammary gland sections were stained for AREG (green) and counterstained with DAPI (blue). C) 
Quantification of AREG staining normalized to total number of DAPI+ cells. Scale bars represent 50 µm. *p<0.05. 
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Figure 2.13. ERα expression is not affected by deletion of STAT5 in macrophages 
[Top] Paraffin-embedded mammary gland sections were stained for ERα and counterstained with hematoxylin. 
[Bottom] Magnification of epithelial structures. Black arrowheads indicate ER+ cells and white arrowheads indicate 
ER- cells. Scale bars represent 50 µm. 
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Figure 2.14. Estrous cycle is normal in STAT5ΔMϕ mice 
  
Crystal violet staining of vaginal lavage fluid from STAT5fl/fl and STAT5ΔMϕ mice. Scale bars represent 100 µm. 
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Figure 2.15. Serum estradiol levels are similar between STAT5fl/fl and STAT5ΔMϕ mice 
Serum concentrations of estradiol from 6-week-old, estrous-staged female mice detected by ELISA. Serum was 
collected during diestrus. 
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BMDMs were treated with conditioned media from HC-11 cells, a non-transformed 
mouse mammary epithelial cell line. This system has biological relevance, as BMDMs 
have been previously shown to be recruited to the mammary gland [143] and HC-11 cells 
retain many characteristics of normal mammary epithelium, including hormone 
responsiveness, milk protein production, and the ability to form mature mammary ducts 
in a cleared fat pad [241,249]. To determine if macrophages express aromatase in 
response to soluble factors produced by mammary epithelial cells, primary BMDMs were 
differentiated from STAT5fl/fl and STAT5ΔMϕ mice and exposed to conditioned media 
from HC-11 cells. Expression levels of Cyp19a1 were significantly increased in STAT5-
deficient macrophages compared to STAT5fl/fl BMDMs (Figure 2.17A). To assess 
whether STAT5 is bound to the Cyp19a1 gene under basal conditions to repress 
aromatase expression, chromatin immunoprecipitation (ChIP) using primers that span the 
predicted STAT5 binding site (Figure 2.16, arrowheads) demonstrated significantly 
enhanced enrichment of target DNA compared to isotype control (Figure 2.17B). 
Complementing these studies, STAT5 ChIP in primary BMDM from STAT5fl/fl mice 
demonstrated enrichment for STAT5 at the Cyp19a1 locus, which is not observed in 
BMDM from STAT5ΔMϕ mice (Figure 2.17C). These results suggest that STAT5 is a key 
regulator of Cyp19a1 expression in macrophages. 
 
To confirm that aromatase expression is increased in vivo, we examined 
mammary glands from STAT5fl/fl and STAT5ΔMϕ mice by immunohistochemistry. 
Consistent with published studies [250], immunohistochemical staining of mammary  
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glands from control STAT5fl/fl mice revealed no detectable aromatase expression in either 
the stromal or epithelial cells (Figure 2.18). However, aromatase expression was readily 
detectable in stromal cells in mammary glands from STAT5ΔMϕ mice (Figure 2.18). The 
stromal cell population surrounding epithelial structures is generally comprised of 
multiple cell types, including macrophages and fibroblasts, suggesting that in addition to 
directly regulating Cyp19a1 expression, loss of STAT5 in macrophages may also lead to 
production of a factor that induces aromatase in other stromal cells. Thus, additional 
studies were performed that focus on identifying factors that could regulate Cyp19a1 
expression. 
 
Pro-inflammatory cytokines release the STAT5-dependent repression of aromatase  
Local production of estrogen in the mammary gland has been implicated in the 
context of obesity [250] and women with a body mass index (BMI) greater than 30 kg/m2 
have a more than two-fold increased risk of developing ER+ breast cancer compared to 
women with BMI less than 25 kg/m2 [165]. IL-6 is a key inflammatory cytokine 
associated with obesity [251] and is known to induce Cyp19a1 expression in endometrial 
cancer stromal cells [166]. Because IL-6 is a key inducer of aromatase in some cell types, 
we set out to address whether IL-6 could regulate Cyp19a1 expression in macrophages. 
Analysis of cytokine expression in STAT5-deficient macrophages revealed increased 
expression of IL-6 (Figure 2.19A). Therefore, we examined the hypothesis that IL-6 
enhances expression levels of Cyp19a1 in macrophages, which has not been previously 
examined. IL-6 stimulation of RAW264.7 macrophages led to increased expression of 
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Figure 2.18. Increased aromatase expression in mammary glands of STAT5ΔMϕ mice 
[Top] Paraffin-embedded mammary gland sections were stained for aromatase and counterstained with 
hematoxylin. Regions identified in squares magnified in insets. [Bottom] Immunohistochemical staining without 
primary antibody as negative control. Scale bars represent 50 µm. 
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Cyp19a1 (Figure 2.19B). Furthermore, we found that treatment of RAW264.7 cells with 
IL-6 led to reduced occupancy of STAT5 at the Cyp19a1 promoter (Figure 2.19C). While 
STAT5 appears to be a critical negative regulator of Cyp19a1 expression, we sought to 
identify factors downstream of IL-6 signaling which could positively regulate Cyp19a1 
expression. In macrophages, the related transcription factor STAT3 is a crucial mediator 
of IL-6 signaling. STAT3 and STAT5 have similar consensus sequences in the genome 
and, in other cell types, it has been shown that the two factors can antagonize each other 
at the same binding site [252,253]. Thus, we hypothesized that upon IL-6 stimulation, 
STAT3 would be recruited to the Cyp19a1 gene, displace STAT5 and activate 
transcription. Indeed, while STAT3 is not bound to the Cyp19a1 gene locus under basal 
conditions, IL-6 treatment of macrophages led to the recruitment of STAT3 to the 
identified binding site in the Cyp19a1 gene (Figure 2.19D). These data suggest that 
STAT5 normally binds the Cyp19a1 gene to suppress gene expression and that exposure 
of macrophages to the inflammatory cytokine IL-6 leads to displacement of STAT5 from 
the promoter, recruitment of STAT3 and increased expression of Cyp19a1. 
 
 
Discussion 
Genetic ablation and biochemical depletion studies have demonstrated that 
macrophages play a vital role in both mammary gland development and tumorigenesis 
[55,140,143-145,232]. The results of our studies illustrate a novel mechanism by which 
macrophages regulate normal mammary gland development and demonstrate that  
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C D 
A B 
Figure 2.19. Inflammatory cytokines alter the balance of STAT3/STAT5 binding at Cyp19a1 locus 
A) mRNA expression of Cyp19a1 in STAT5fl/fl and STAT5ΔMϕ BMDM. B) Cyp19a1 mRNA expression in 
RAW264.7 macrophages stimulated with IL-6. n=6 per treatment. C) Fold enrichment of Cyp19a1 in RAW264.7 
macrophages +/- IL-6 for 2 hours by ChIP using STAT5-specific antibody or isotype control. Representative 
experiment of three replicates shown. D) Fold enrichment of Cyp19a1 in RAW264.7 macrophages +/- IL-6 for 30 
minutes by ChIP using STAT3-specific antibody or isotype control. Representative experiment of three replicates 
shown. *p<0.01, ****p<0.0001. 
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perturbations to the STAT5 signaling axis in these cells can increase susceptibility to 
oncogenic initiation. In the normal mammary gland, STAT5 signaling is activated in 
macrophages associated with epithelial structures and may be a critical factor in 
regulating macrophage function. Using genetic approaches, we have generated mice with 
a deletion of both alleles of Stat5a and Stat5b in cells of the myeloid lineage 
(STAT5ΔMϕ). In contrast to the global double knockout mice, STAT5ΔMϕ are viable and 
fertile, with no gross abnormalities apparent, demonstrating that function of STAT5 
signaling in macrophages is distinct from its function in other cell types [226]. Upon the 
loss of STAT5 in macrophages, mammary gland development is significantly altered, 
with decreased ductal elongation, increased lateral branching, and increased epithelial 
proliferation. These alterations were associated with increased levels of ER target genes. 
While the Csf1r-iCre transgene is expressed primarily in myeloid cells, certain subsets of 
splenic dendritic cells and T cells exhibit low levels of Cre-mediated gene deletion [239]. 
Given the requirement for macrophages during mammary gland development and the 
well-described infiltration of macrophages [140,144-146,232], our studies focused on this 
cell population. However, these studies do not rule out the possibility that deletions in 
small subsets of less abundant cell types may contribute to the phenotypes observed in 
these mice. Previous studies have investigated the role of STAT5 specifically in 
mammary epithelial cells. In contrast to our observations of STAT5 deletion in 
macrophages, mammary epithelial cell-specific deletion of STAT5 does not alter pubertal 
development, but instead results in decreased epithelial proliferation in response to 
estrogen and progesterone [95,96,221-224]. Because secreted factors that activate STAT5 
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are present in the mammary gland during other stages of development, future studies will 
examine STAT5 function in macrophages during additional stages of mammary gland 
development.  
 
Hormone signaling is a very well-regulated process in normal tissues. However, 
during pathologic conditions such as obesity and breast cancer, this axis can become 
perturbed through increased production of estrogen via the enzyme aromatase. Numerous 
studies have elucidated the role of hormone signaling in the developing mammary gland 
using tissue transplant techniques. Estrogen signaling is required in mammary epithelial 
cells, not stromal cells, to facilitate proper ductal elongation, as ERα-null epithelial cells 
remain in a rudimentary ductal tree and do not invade through the fat pad [99]. At the 
same time however, an excess of estrogen signaling can also lead to reduced ductal 
elongation [104]. Increased ER signaling leads to the production of growth factors, such 
as AREG, which can drive mammary epithelial cell proliferation and lateral branching 
[245,254,255]. Thus, instead of invading through the fat-pad longitudinally, increased 
estrogen signaling may lead to proliferation laterally across the fat pad prematurely. 
 
While numerous roles have been ascribed to macrophages in the tumor 
microenvironment, less is known regarding their functions during normal mammary 
gland development. Consistent with their role in innate immunity, macrophages are a cell 
type with a high degree of plasticity and can respond to various signals in the 
microenvironment rapidly. Because macrophages are already associated with the 
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developing epithelial structures, it is logical that they can also assist in orchestrating 
developmental processes [138,140,144]. Previous studies have shown that macrophages 
affect collagen organization surrounding terminal end buds in the mammary gland [145]. 
Our studies suggest that macrophages contribute to proper ductal elongation in a manner 
that requires STAT5. We have also identified a novel mechanism by which STAT5 
regulates expression of aromatase, suggesting that macrophages may provide a local 
source of estrogen during mammary gland development. Ovarian-derived estrogen is a 
well-established regulator of ductal elongation in the mammary gland [93]. However, 
given the heterogeneity of epithelial proliferation in the mammary gland, it seems 
feasible that macrophages may contribute small amounts of estrogen to help pattern 
proliferative areas or branching along the ducts. This suggests a novel potential function 
for tissue resident macrophages during mammary gland development and is consistent 
with previous studies that have suggested that macrophages are capable of synthesizing 
estrogen in the context of breast cancer [155]. In addition, STAT5 is known to regulate 
expression of numerous genes in other cell types and it is possible that additional STAT5-
regulated genes may contribute to macrophage function in the mammary gland [256-
258]. 
 
Previous work has demonstrated a role for STAT5 tetramers in repressing gene 
expression through chromatin modifications and STAT5 binding patterns in the genome 
can be affected by upstream signaling through numerous different receptors [247,248]. 
Additionally, many STAT5-dependent target genes are regulated by EZH2-mediated 
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histone methylation [256]. Thus, during mammary gland development, signaling in 
macrophages downstream of cytokine and growth factor receptors may affect genomic 
STAT5 binding locations and relieve STAT5 tetramer-mediated gene repression. This 
may allow aromatase to be expressed and estrogen to be produced in a very local setting, 
acting in a short-range paracrine manner to further enhance epithelial proliferation. In 
addition to altering STAT5-mediated repression directly by changing tetramer binding 
frequency, repression can also be overcome by activating additional transcription factors 
with cytokines. Indeed, IL-6 treatment leads to a marked reduction in STAT5 occupancy 
at the Cyp19a1 promoter within 2 hours of treatment and is sufficient to induce binding 
of STAT3 and induction of Cyp19a1 gene expression. Moreover, the increased 
production of IL-6 by macrophages can act on additional stromal cells, such as fibroblasts 
and adipocytes, to further enhance stromal aromatase expression, which could explain the 
enhanced expression of stromal aromatase observed in Figure 4E. These data provide 
possible insight into why, in the context of obesity which is often associated with 
increased IL-6 levels, patients have an increased risk of developing ER+ breast cancers 
[165]. While our studies focus on the repressive nature of STAT5 binding at the Cyp19a1 
promoter, future studies are warranted to further characterize the transcription factors 
involved in the positive regulation of Cyp19a1. Given that STAT3 is a major 
transcription factor downstream of IL-6 signaling, it is plausible that STAT3 may be one 
of the factors required to promote the expression of Cyp19a1. Recent studies have 
illustrated that the activation of STAT3 is able to antagonize STAT5 binding to 
consensus sites in the genome [259]. Moreover, work in Th17 cells has demonstrated that 
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retinoic acid treatment promotes STAT5 binding in the Il17a locus, while IL-1β 
treatment leads to the activation and the preferential recruitment of STAT3 to the binding 
site shared by STAT5 [253]. Additionally, the loss of STAT5 led to increased binding of 
STAT3 to the shared consensus sequence in the Il17a locus. While our data demonstrate 
that STAT3 is recruited to the Cyp19a1 locus following IL-6 treatment, we cannot yet 
conclude whether IL-6 directly induces Cyp19a1 expression through transcriptional 
activation by STAT3 or indirectly through antagonizing STAT5-mediated transcriptional 
repression. 
 
In summary, we have identified the transcription factor STAT5 as an important 
regulator of resident macrophage function in the developing mammary gland.  Using 
genetic approaches, we have generated mice harboring a deletion of both alleles of Stat5a 
and Stat5b in macrophages. The loss of STAT5 signaling in macrophages results in 
altered mammary gland morphogenesis and increased expression of aromatase, 
correlating with increased estrogen production and ER signaling. Understanding how 
STAT5 signaling in resident macrophages shapes the microenvironment will inform 
future studies of modulating JAK/STAT signaling with pharmacologic inhibitors and 
identify new targets for combination therapies to improve treatment efficacy and patient 
outcome. 
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Chapter 3. Mammary Tumorigenesis is Accelerated by the Loss of 
STAT5 in Macrophages 
 
Introduction 
The tumor microenvironment is a heterogeneous collection of various cell types, 
extracellular matrix factors, cytokines, chemokines, and growth factors [156]. Cells of the 
macrophage lineage represent critical cellular constituents of this tumorigenic milieu. 
Tumor-associated macrophages (TAMs) can modulate the microenvironment and 
promote tumorigenesis through a variety of mechanisms, including indirect methods such 
as neo-angiogenesis, matrix remodeling, and suppression of adaptive immune responses 
as well as direct methods such as promoting tumor growth, survival, invasion, and 
metastasis [260]. Clinically, TAM density is correlated with poor patient prognosis, with 
higher amounts of TAM infiltration being associated with reduced overall survival in 
breast cancer patients [238]. Because macrophages can promote tumorigenesis in many 
diverse ways, they are thought to represent promising therapeutic targets. Indeed, 
numerous antibodies and small molecule inhibitors are currently being explored in solid 
tumor clinical trials to reduce or deplete TAMs [261]. In addition to their tumor-
promoting functions, macrophages also have the ability to kill tumor cells by assisting in 
and promoting an anti-tumor adaptive immune response. However, the signaling 
pathways in macrophages which regulate this switch between pro- and anti-tumor 
responses remain unclear. Thus, it is imperative to further identify and characterize 
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regulators of TAM function and behavior in order to develop novel therapies that can re-
educate TAMs to take on an anti-tumor role. 
 
The immune response is a multifactorial process that involves cells of both the 
innate and adaptive immune systems, allowing for the recognition and destruction of 
foreign pathogens and damaged cells. At the same time, this response is tightly controlled 
by both positive and negative regulatory signals to maximize pathogen clearance but 
minimize damage to surrounding tissues. After T cells are recruited to the site of 
inflammation, foreign peptides presented by antigen presenting cells (APCs) are 
recognized and activate the T cells. Additional co-stimulation is required for optimal 
activation, achieved in large part through the binding of CD28 on the surface of T cells to 
CD80 or CD86 on the surface of activated APCs [262]. As a negative regulatory 
mechanism, APCs upregulate the expression of T cell inhibitory factors, such as PD-L1 
and PD-L2. These factors bind to PD-1 on the surface of T cells and suppress their 
function, leading to reduced damage to surrounding tissue and a resolution of the 
inflammatory state. 
 
Anti-tumor immunity is regulated by the same cells and processes as an anti-
pathogen response. The limitation, however, is the lack of clearly-defined foreign 
peptides for the immune system to recognize. Instead, when mounting an anti-tumor 
response, responding immune cells recognize neoepitopes generated by mutations in 
tumor cells or by changes in surface expression of various markers, a concept known as 
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“altered self”. Additionally, tumor cells themselves frequently express immunoregulatory 
molecules on their cell surface, co-opting the normal regulatory mechanism, allowing for 
direct T cell inhibition in the tumor microenvironment, and promoting tumor growth. 
Therapeutic blockade of the suppressive receptors in T cells or targeting of the ligands on 
tumor cells and APCs has had tremendous success in many cancer types [262]. While the 
expression of suppressive ligands on TAMs has been well-documented [263], much is 
still unknown about the signaling pathways in TAMs that directly control the expression 
of these factors. 
 
The role of STAT5 has been extensively studied in many immune cell subsets. 
Proper T cell activation and survival require IL-2, which signals downstream through 
STAT5. Studies using STAT5-deficient mice revealed a complete block in lymphocyte 
development and implicated STAT5 in the proliferation of thymocytes and the lineage 
commitment between CD4+ and CD8+ T cells [226,227]. Moreover, studies using a 
constitutively active form of STAT5 have demonstrated increased regulatory T cell 
differentiation [264]. STAT5 has also been shown to be a critical regulator of DC 
function. STAT5-deficient DCs fail to promote a TH2 response in T cells, while TH1 
responses are unaffected [228]. These data reveal that STAT5 regulates specific immune 
responses and can modulate the interface between innate and adaptive immunity. While 
much is known regarding the function of STAT5 in lymphoid cells and DCs, the role of 
STAT5 signaling in macrophages is relatively unknown. Previous studies have 
implicated STAT5 as a downstream mediator of M2 macrophage polarization in response 
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to IL-3 [229], but no studies have directly assessed the contribution of STAT5 signaling 
to macrophage-mediated regulation of the adaptive immune response. 
 
Results of the studies performed in Chapter 2 suggest that the loss of STAT5 
signaling in macrophages leads to the development of a microenvironment that is 
permissive for breast cancer initiation. The studies described here seek to address if the 
loss of STAT5 in macrophages affects tumor growth and progression, whether STAT5 is 
a regulator of TAM function, and how STAT5 signaling in macrophages could 
potentially modulate adaptive immune responses. 
 
Materials and Methods 
Mice. Csf1r-iCre mice were provided by Dr. Elaine Lin [239] on the FVB background 
and Stat5fl/fl mice were provided by Dr. Lothar Hennighausen [95]. For iFGFR1 
activation, mice were injected twice weekly with 1 mg/kg B/B homodimerizer (Clontech) 
by intraperitoneal injection as previously described [55,60]. Athymic nude mice and 
wild-type BALB/c mice were purchased from Harlan Laboratories and both the Csf1r-
iCre and Stat5fl/fl mice were backcrossed to the BALB/c background. Successful 
backcrossing was verified using congenic analysis (IDEXX-RADIL, Columbia, MO). 
Mice were anesthetized with isoflurane and 1x104 4T1-luc cells or 5x105 HC-11/R1-luc 
cells suspended in 50% Matrigel (BD Biosciences) were injected into the fourth inguinal 
mammary fat pad. Tumor burden was assessed by caliper measurement. For iFGFR1 
activation, mice were injected twice weekly with 1 mg/kg B/B homodimerizer (Clontech) 
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by intraperitoneal injection as previously described [55,60]. For PD-L2 blockade, mice 
were injected with 200 µg of an anti-PD-L2 antibody (BioXcell) or isotype control 
antibody every other day by intraperitoneal injection. Two hours prior to sacrifice, mice 
were injected with 30 mg/kg BrdU by intraperitoneal injection. All animal care and 
procedures were approved by the Institutional Animal Care and Use Committee of the 
University of Minnesota and were in accordance with the procedures detailed in the 
Guide for Care and Use of Laboratory Animals. 
 
Mammary gland whole mounts. Mammary glands were harvested and fixed in 4% 
paraformaldehyde for 2 hours, rinsed in 70% ethanol and stained in Carmine alum 
overnight. Glands were dehydrated using 70%, 95%, and 100% ethanol then cleared in 
xylene. Stained glands were imaged and subsequently stored in methyl salicylate. 
Quantification of epithelial area was performed on 8-bit images using ImageJ. 
 
Bioluminescent imaging (BLI). Mice were injected with 150 mg/kg D-luciferin (Gold 
Bio) via intraperitoneal injection 10 minutes prior to imaging. Mice were anesthetized 
with isoflurane and BLI was acquired using a Xenogen IVIS 100 (University of 
Minnesota Imaging Center). Data analysis was performed using Living Image software.  
 
Immunoblot analysis. Protein lysates were subjected to SDS-PAGE using 20 µg total 
protein. Immunoblot analysis was performed using antibodies listed in the Appendix. 
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Cell culture. HC-11 and HC-11/R1 cells were maintained as previously described 
[60,241]. RAW264.7 cells, Hs578T cells, and MDA-MB-231 cells were grown in media 
containing DMEM (Life Technologies) supplemented with 10% FBS and 1% 
penicillin/streptomycin (Life Technologies). MCF-7 cells were grown in the same media 
as above but were additionally supplemented with 10 µg/mL insulin. DCIS cells were 
grown in media containing DMEM/F-12 (Lonza) supplemented with 5% horse serum. 
MCF-10A cells were grown in the same media as DCIS but were additionally 
supplemented with insulin, EGF, cholera toxin, hydrocortisone and 
penicillin/streptomycin as previously described [265]. THP-1 cells were grown in media 
containing RPMI supplemented with 10% FBS and 1% penicillin/streptomycin (Life 
Technologies) and subsequently differentiated to macrophages using 5 ng/mL phorbol 
12-myristate 13-acetate (PMA). Bone marrow was flushed from the femurs and tibiae of 
mice and plated overnight in DMEM + 10% FBS. Non-adherent cells were collected and 
re-plated in low-attachment plates with DMEM + 10% FBS + 20% conditioned media 
from L929 cells, a cell line that produces high levels of macrophage-colony stimulating 
factor. Differentiated macrophages were subsequently re-plated in normal tissue culture 
dishes for experiments. 
 
Lentivirus production. A lentiviral plasmid with a bi-directional promoter was a gift of 
Dr. Beau Webber (University of Minnesota). This plasmid stably expresses firefly 
luciferase driven by the PGK promoter as well as GFP driven by the EF-1α promoter 
(pHIV-PGK.Luc-EF1a.GFP). Expression plasmid and Trans-Lentiviral Packaging Mix 
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(Open Biosystems) were transfected into the HEK293T packaging cell line. Cell culture 
supernatant was collected after 24 and 48 hours, concentrated using Lenti-X Concentrator 
(Clontech), and stored at -80°C until use. 
 
Generation of HC-11/R1-luc cells. HC-11/R1 cells were plated at a density of 1x105 
cells per well of a 6-well plate. Lentiviral transduction was performed in the presence of 
12.5 µg/mL polybrene. FACS was performed on transduced cells using a BD FACSAria 
II at the University of Minnesota Flow Cytometry Resource. Single GFP+ cells were 
sorted to individual wells of a 96-well plate for single cell cloning while remaining bulk 
GFP+ cells were retained for population analysis. 
 
Luciferase activity assay. Expression of luciferase was detected using the Luciferase 
Assay System (Promega). For analysis, 4x105 cells were transferred to a microcentrifuge 
tube and pelleted at 7,000 x g for 5 minutes. Cell pellets were lysed in 300 µL Cell 
Culture Lysis Buffer and 8 µL of resulting lysates were combined with 30 µL Luciferase 
Assay Substrate reagent and subsequently read on a luminometer for 2 seconds. 
 
qRT-PCR. Cells were cultured as described above, RNA harvested using TriPure 
Reagent (Roche) and quantitative reverse transcription PCR was done as previously 
described [67] using qScript cDNA SuperMix and PerfeCTa SYBR Green SuperMix 
(Quantabio). Gene expression was normalized to Ppib (cyclophilin B) levels. Primer 
sequences used are listed in the Appendix. 
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ChIP. RAW264.7 macrophages were plated at 3x106 cells per plate in a 10cm plate in 
DMEM + 10% FBS overnight. Cells were subsequently washed and serum-starved in 
DMEM overnight and fixed or treated with 50 ng/mL IL-6 as indicated before being 
fixed. Primary BMDMs were plated at 5x105 cells per 6cm plate and grown for 48 hours. 
Cells were subsequently washed and serum-starved in DMEM for 4 hours and fixed or 
treated with 50 ng/mL IL-6 as indicated before being fixed. ChIP was performed with a 
STAT5-specific antibody (sc-836X, Santa Cruz) or non-specific rabbit IgG isotype 
control using Protein G magnetic beads (Active Motif). Analysis was performed using 
methods as previously described [242]. All ChIP data presented are normalized to % 
input chromatin and presented as fold enrichment over IgG control. Primers sequences 
are listed in the Appendix. 
 
Immunohistochemistry and immunofluorescence. Tumors and lungs were harvested, 
fixed in 4% paraformaldehyde for 2 hours, sectioned and stained as previously described 
[55] using conditions listed in the Appendix. All images were acquired using Leica LAS 
software. 
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Results 
Tumor-derived soluble factors activate STAT5 in macrophages 
Complex interactions between tumor cells and stromal cells take place in the 
tumor microenvironment and are mediated by soluble factors [156], including many that 
signal through the STAT signaling pathway. To model tumor/stroma interactions in vitro 
and determine how tumor cells modulate TAM function, CM from breast cancer subtypes 
representing a spectrum of clinical and molecular subtypes were collected and used to 
stimulate macrophages. While few effects were observed in response to soluble factors 
from non-transformed epithelial cells, pre-invasive tumor cells, or ER+ tumor cells 
analysis of protein lysates demonstrated robust activation of STAT5 in macrophages 
following treatment with TNBC-derived soluble factors (Figure 3.1). These data suggest 
that, in addition to its role in regulating normal mammary gland development, STAT5 
signaling in macrophages may be critical during tumorigenesis. 
 
Accelerated formation of hyperplasias in STAT5ΔMϕ mice 
Based on the findings that deletion of STAT5 in macrophages is associated with 
increased estrogen signaling and the enhanced production of factors involved in 
mammary tumorigenesis, we predicted that loss of STAT5 in macrophages would lead to 
the formation of an environment that is permissive for pre-neoplastic alterations. In 
previous studies, we have used an inducible model of FGFR1 activation to study 
mechanisms that drive early stages of mammary tumorigenesis [55,266]. These studies 
use transgenic mice that express an inducible FGFR1 (iFGFR1) construct, under the  
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Figure 3.1. STAT5 in macrophages is activated by TNBC-derived soluble factors 
Immunoblot of THP-1 macrophages treated with CM as indicated. β-tubulin is shown as a loading control. 
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control of the mouse mammary tumor virus (MMTV) promoter, which can be activated 
by intraperitoneal injection of B/B homodimerizer (Clontech) [60] (Figure 3.2). 
Activation of iFGFR1 in the mammary gland results in the formation of budding 
epithelial structures along the duct [55,60]. The inducible nature of this model allows for 
the temporal control of FGFR1 activation and the ability to discern how pre-existing 
alterations in the tissue microenvironment, such as alterations in systemic or localized 
inflammatory signals, contribute to early stages of tumorigenesis upon acquisition of a 
somatic mutation. To determine how the loss of STAT5 in macrophages affects the 
formation of early stage lesions in this model, STAT5fl/fl and STAT5ΔMϕ mice were 
crossed with the MMTV-iFGFR1 mice. Consistent with previous reports [55,60], 
activation of iFGFR1 for 2 weeks in STAT5fl/fl ; MMTV-iFGFR1+ mice resulted in the 
formation of budding epithelial structures along the duct (Figure 3.3A). In contrast, the 
same timecourse of iFGFR1 activation in STAT5ΔMϕ ; MMTV-iFGFR1+ mice led to a 
profound increase in the size and severity of epithelial buds and instances of local 
hyperplasia (Figure 3.3A). Quantification of epithelial area demonstrated an increased 
amount of epithelium in the hyperplastic lesions of the STAT5ΔMϕ ; MMTV-iFGFR1+ 
mice (Figure 3.3B). Analysis of BrdU incorporation revealed that while activation of 
FGFR1 signaling in the epithelial cells resulted in increased proliferation, the loss of 
STAT5 in macrophages further enhanced this proliferation (Figure 3.3C). Similar to the 
findings in the normal mammary gland, STAT5 expression in macrophages is 
dispensable for their recruitment to the budding epithelial structures (Figure 3.4). Taken 
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Figure 3.3. Accelerated mammary tumor initiation in STAT5ΔMϕ mice 
  
A B 
C 
A) Mammary gland whole mounts from mice treated with B/B dimerizer for 2 weeks. Arrows indicate regions of 
hyperplasia. B) Quantification of epithelial area in hyperplastic lesions from STAT5fl/fl ; iFGFR1+ and STAT5ΔMϕ ; 
iFGFR1+ mice. C) [Left] Paraffin-embedded mammary gland sections from mice after 2 weeks of iFGFR1 
activation were stained for BrdU (red) to assess proliferation and counterstained with DAPI (blue). [Right] 
Quantification of proliferating cells normalized to total number of DAPI+ cells. Scale bars represent 100 µm. 
*p<0.05. 
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Figure 3.4. STAT5 is dispensable for macrophage recruitment to budding epithelial lesions 
Immunohistochemical staining of mammary glands from STAT5fl/fl and STAT5ΔMϕ mice. Sections were stained for 
F4/80 and counterstained with hematoxylin. Scale bars represent 50 µm. 
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together, these results demonstrate that STAT5 deletion in macrophages pre-disposes the 
mammary gland to enhanced formation of epithelial hyperplasias. 
 
Creation of HC-11/R1-luc cells 
The use of genetically-modified cell lines has provided researchers with the 
necessary tools to study the process of malignant progression. To model breast cancer 
development in a clinically-relevant way, a non-transformed mouse mammary epithelial 
cell line, HC-11, was retrovirally transduced to stably express iFGFR1 [60]. The resulting 
cells, termed HC-11/R1 cells, can be activated with B/B homodimerizer (Clontech) 
leading to the forced dimerization of iFGFR1 molecules and downstream signaling 
through the MAPK, STAT and Akt pathways (Figure 3.2). To further improve the 
usefulness of HC-11/R1 cells as an in vivo tumor model, efforts were undertaken to 
stably express an enzyme, firefly luciferase, which permits the tracking of labeled cells 
through non-invasive imaging modalities. HC-11 and HC-11/R1 cells were transduced 
with a lentivirus expressing both firefly luciferase and GFP and subjected to FACS. Both 
cell types were successfully transduced, albeit with low efficiency (Figure 3.5A). Bulk 
GFP+ cells were sorted from the GFP- cells and luciferase expression was detected using 
a luciferase assay system. Sorted GFP+ HC-11 and GFP+ HC-11/R1 cells both 
demonstrated robust luciferase activity compared to parental HC-11 and HC-11/R1 cells 
(Figure 3.5B). The resulting luciferase-positive cells were named HC-11-luc and HC-
11/R1-luc, to indicate their stable expression of luciferase and GFP. Because these 
populations were a heterogeneous collection of cells, single-cell cloning was undertaken 
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Figure 3.5. Creation of luciferase-expressing HC-11 and HC-11/R1 cells 
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to generate subclones with consistent GFP and luciferase expression. One single-cell 
clone was obtained from the HC-11-luc cells (Clone D4) while two independent single-
cell clones were generated from the HC-11/R1-luc cells (Clone B2 and Clone H2). To 
verify that the single-cell clones remained representative of the bulk population, a 
luciferase assay was performed on protein lysates from HC-11/R1-luc Clone B2 and 
Clone H2. Analysis revealed strong luciferase activity in both single-cell clones while 
activity in parental HC-11 and HC-11/R1 cells remained undetectable (Figure 3.6A/B). In 
addition to retaining luciferase activity, the subcloned lines must retain the ability to 
respond to B/B homodimerizer by activating iFGFR1. Parental HC-11 and HC-11/R1 
cells along with subcloned HC-11-luc and HC-11/R1-luc cells were treated with B/B to 
assess iFGFR1 activation as measured by STAT3 activation. Parental HC-11/R1 cells 
demonstrated strong STAT3 activation after 2 and 6 hours of B/B treatment compared to 
ethanol solvent control (Figure 3.6C). Analysis of Clone B2 revealed STAT3 activation 
in the presence of B/B but at a substantially reduced level compared to parental cells, 
while Clone H2 showed little to no responsiveness to B/B (Figure 3.6C). As expected, 
parental HC-11-luc and Clone D4 showed no STAT3 activation in response to B/B, as 
both cell lines lack the iFGFR1 construct (Figure 3.6C). Because Clone B2 retained at 
least partial responsiveness to B/B, this clone was chosen for further development and 
use in vivo (simply denoted as HC-11/R1-luc for the remainder of this work). To initially 
characterize the molecular subtype of the HC-11/R1-luc cells, gene expression analysis 
was performed on cells treated with B/B or solvent control. Interestingly, activation of 
iFGFR1 led to the induction of a gene expression program that is consistent with the 
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Figure 3.6. Single-cell cloning of HC-11-luc and HC-11/R1-luc 
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 claudin-low molecular subtype of TNBC (Figure 3.7A). In addition to the claudin-low 
phenotype, activation of iFGFR1 was also sufficient to induce transcriptional changes 
associated with epithelial-mesenchymal transition (Figure 3.7B). In an initial pilot study 
to assess tumorigenic potential of the newly-created cell line, HC-11/R1-luc cells were 
injected into the mammary fat pad of a wildtype BALB/c mouse and B/B was 
subsequently administered by i.p. injection. After 5 weeks, BLI revealed measurable 
signal in the mammary gland which steadily increased over time, while a palpable mass 
was observed by week 7 after transplant (Figure 3.8). These data demonstrate that the 
HC-11/R1-luc cells may serve as a model of the claudin-low subtype of TNBC, retain 
tumorigenic potential when treated with B/B, and can be followed over time using BLI-
based approaches. 
 
Loss of STAT5 in macrophages accelerates mammary tumorigenesis 
Because previous results suggested that STAT5 signaling in macrophages could 
modulate pro-tumor behavior, the STAT5 conditional knockout mice (STAT5ΔMϕ) were 
backcrossed to the BALB/c background to facilitate tumorigenesis studies in an 
immunocompetent setting. Seven days after orthotopic injection of HC-11/R1-luc cells 
into the mammary fat pads of STAT5fl/fl and STAT5ΔMϕ mice, positive luciferase signal 
indicated successful delivery of tumor cells. However, striking differences were revealed 
over time in the ability of transplanted cells to persist and form tumors. While luciferase 
signal was readily detected in mammary glands from STAT5ΔMϕ mice and increased over 
time, mammary glands from STAT5fl/fl mice demonstrated a steady reduction in  
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Figure 3.8. Assessment of tumorigenic potential of HC-11/R1-luc cells 
[Top] Longitudinal luciferase imaging of mouse after orthotopic injection of HC-11/R1-luc cells into the mammary 
fat pad. iFGFR1 activation was achieved by i.p. injection of B/B for 5 weeks prior to beginning the imaging. 
[Bottom] Quantification of luciferase imaging pictured above. 
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luciferase signal over time and eventual loss of any detectable signal from all animals 
(Figure 3.9). In fact, more than 50% of STAT5fl/fl mice had lost luciferase expression 
within the first 14 days following injection of cells, while the remaining 50% of the mice 
lost expression of luciferase in the following 7 weeks (Figure 3.9). Clearance of tumor 
cells is mediated primarily by cells of the adaptive immune system, mainly CD8+ T 
lymphocytes. To address if adaptive immunity was responsible for the observed 
differences in tumor cell persistence and proliferation, HC-11/R1-luc cells were injected 
into the mammary fat pads of athymic nude mice, which lack functional B and T 
lymphocytes but retain normal innate immune function. Strikingly, luciferase signal was 
readily detected in athymic nude mice, increased steadily over time, and recapitulated 
results observed in STAT5ΔMϕ mice (Figure 3.9). Because no tumors were observed in 
STAT5fl/fl mice, orthotopic injections were repeated in both STAT5fl/fl and STAT5ΔMϕ 
mice using the parental HC-11/R1 cells. Similar to the results observed with the HC-
11/R1-luc cells, transplant of the parental cells resulted in tumor formation in STAT5ΔMϕ 
mice. With this model, tumor formation was observed in STAT5fl/fl mice, albeit at a 
reduced frequency compared to the STAT5ΔMϕ mice (Figure 3.10A). In addition to 
differences in primary tumor formation between STAT5fl/fl and STAT5ΔMϕ mice, the 
presence of metastatic lesions was observed in the lungs of STAT5ΔMϕ mice (Figure 
3.10B). However, no metastatic deposits were observed in STAT5fl/fl mice with similar 
primary tumor burden. 
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Figure 3.10. Increased metastatic burden in the lungs of STAT5ΔMϕ mice 
  
HC-11/R1 Tumor Survival
0 20 40 60
0
50
100
Pe
rc
en
t S
ur
vi
va
l (
%
)
Days Elapsed
STAT5fl/fl
STAT5ΔMΦ *
Lung Metastasis in STAT5DMf Mice
STAT5 DMf
10x H&E 40x H&E
A 
B 
A) Overall survival of STAT5fl/fl and STAT5ΔMϕ mice with orthotopic injection of parental HC-11/R1 cells. B) 
[Left] 10x magnification of H&E stained lung sections from a tumor-bearing STAT5ΔMϕ mouse. [Right] 40x 
magnification of metastatic lesion. n=8 (STAT5fl/fl) and n=5 (STAT5ΔMϕ). *p<0.05. 
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 The HC-11/R1-based transplant models are relatively less aggressive compared to 
other mouse models of mammary tumorigenesis. To assess the role of STAT5 signaling 
in macrophages during tumorigenesis using a more aggressive model, orthotopic 
transplants were performed using the 4T1-luc cell line. These cells are derived from a 
spontaneously-arising mammary tumor in a pregnant BALB/c mouse [267]. In addition to 
being aggressive and highly metastatic to the lung, this cell line has also been engineered 
to stably expresses firefly luciferase, thus allowing for tracking by in vivo BLI. 
Luciferase imaging after transplant revealed the presence of tumor cells in all animals of 
both genotypes. Similar to the findings in the HC-11/R1-luc model, luciferase signal 
increased steadily over time in the STAT5ΔMϕ mice (Figure 3.11A). In contrast to the HC-
11/R1-luc model, however, STAT5fl/fl mice retained low-levels of detectable luciferase 
signal and developed palpable tumors, which were comprised mainly of luciferase-
negative cells (Figure 3.11A). Additionally, while all mice of both genotypes developed 
tumors in this study, tumors reached a volume of 1 cm3 significantly faster in STAT5ΔMϕ 
mice (Figure 3.11B/C). Moreover, while both genotypes had equivalent primary tumor 
burden at the endpoint, STAT5ΔMϕ mice had increased metastatic burden in the lungs 
compared to STAT5fl/fl tumor-bearing mice (Figure 3.11D). Taken together, these data 
suggest that the loss of STAT5 in macrophages promotes mammary tumorigenesis and 
metastasis, possibly through regulating adaptive immunity. 
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Figure 3.11. Increased 4T1 tumor growth and metastasis in STAT5ΔMϕ mice  
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STAT5 suppresses PD-L2 expression in macrophages 
The observed tumor clearance and reduced luciferase signal in the STAT5fl/fl 
mice, combined with the ability of the HC-11/R1-luc cells to form tumors in athymic 
nude mice, suggested that STAT5 in macrophages may be a critical regulator of the 
crosstalk between innate and adaptive immunity. To address this, targeted qRT-PCR was 
performed in WT or STAT5-deficient BMDMs after stimulation with CM from HC-
11/R1 cells to investigate the expression of T cell co-stimulatory and immunoregulatory 
factors. While no differences in expression were observed for the co-stimulatory factor 
Cd80 or the checkpoint molecule Cd274 (PD-L1) (data not shown), a decrease in the 
expression of Cd86 was observed in STAT5-deficient macrophages, along with a 
corresponding increase in the expression of Pdcd1lg2 (PD-L2) (Figure 3.12A). PD-L2 is 
known to be expressed on APCs and is a critical suppressor of anti-tumor immunity. To 
characterize the mechanism by which STAT5 controls PD-L2 expression, the Pdcd1lg2 
locus was examined for potential STAT5 binding motifs. Analysis revealed a canonical 
STAT5 tetramer-binding sequence (2 tandem STAT5 consensus motifs separated by a 10 
bp spacer region) located upstream of the transcriptional start site (TSS) (Figure 3.12B). 
In order to investigate whether STAT5 could bind the predicted tetramer site to suppress 
PD-L2 expression, ChIP was performed in RAW264.7 cells. Under basal conditions, 
STAT5 was found to be bound at the potential tetramer site in the Pdcd1lg2 promoter 
region by a significant enrichment over isotype antibody control (Figure 3.12C). 
Moreover, treatment of macrophages with IL-6 resulted in undetectable STAT5 binding 
at this site, suggesting that STAT5 regulation of PD-L2 expression may be modified by  
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Figure 3.12. STAT5 regulates co-stimulatory and immunoregulatory factors in macrophages 
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soluble factors in the microenvironment (Figure 3.12C). Additionally, ChIP performed in 
primary WT or STAT5-deficient BMDMs revealed STAT5 binding to the Pdcd1lg2 
promoter in WT macrophages that was not present in STAT5-deficient macrophages 
(Figure 3.13). These data suggest that STAT5 negatively regulates PD-L2 expression in 
macrophages. 
 
Blockade of PD-L2 partially reduces mammary tumorigenesis in STAT5ΔMϕ mice 
The PD-1 signaling axis has been intensely studied in recent years and is the 
target of many therapeutic agents. Because STAT5ΔMϕ showed accelerated tumorigenesis 
in multiple tumor models, as well as based on the in vitro data suggesting STAT5 is a 
negative regulator of PD-L2 expression, experiments were performed to assess the ability 
of PD-L2-targeted therapies to alter the course of tumorigenesis in STAT5ΔMϕ mice. 
Beginning 3 days after 4T1-luc cell injection, STAT5ΔMϕ mice were treated with anti-PD-
L2 antibodies or isotype control. Agreeing with previous findings, STAT5ΔMϕ mice 
treated with isotype control antibodies developed tumors and luciferase signal was 
readily detectable (Figure 3.14). However, when treated with anti-PD-L2 antibodies, 
STAT5ΔMϕ mice displayed slightly reduced luciferase signal, partially recapitulating what 
was observed in STAT5fl/fl mice (Figure 3.14). These data suggest that the loss of STAT5 
in macrophages leads to increased PD-L2 expression, which promotes mammary 
tumorigenesis. 
  
  122 
  
Pdcd1lg2 ChIP
Fo
ld
 E
nr
ic
hm
en
t
(N
or
m
al
iz
ed
 to
 In
pu
t)
IgG
ST
AT
5
IgG
ST
AT
5
0
1
2
3
STAT5fl/fl STAT5ΔMφ
*
Figure 3.13. STAT5 binds the Pdcd1lg2 locus in primary BMDMs 
Fold enrichment of Pdcd1lg2 in BMDMs from STAT5fl/fl and STAT5ΔMϕ mice 
under basal conditions. ChIP was performed using a STAT5-specific antibody or 
isotype control. Replicate of three independent experiments shown. *p<0.05. 
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Figure 3.14. Blockade of PD-L2 partially reduces luciferase signal in STAT5ΔMϕ mice 
Quantification of luciferase signal in STAT5ΔMϕ mice treated with anti-PD-L2 antibodies or isotype control. Signal 
normalized to IgG treated mice at each time point after tumor cell implantation. 
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Discussion 
STAT5 signaling in epithelial cells has been shown to promote mammary 
tumorigenesis by regulating cell survival, in part through regulation of the PI3K/Akt 
pathway [268-271]. However, the function of STAT5 in stromal cells found in the tumor 
microenvironment is less well-characterized. Defining the role of STAT5 signaling in 
macrophages has implications for clinical trials in breast cancer and other malignancies. 
Macrophages are known to be found within breast tumors and the increased abundance of 
tumor-associated macrophages is correlated with poor patient outcome [238]. It has also 
been well-documented that genomic amplification of FGFR1 occurs in 10% of all breast 
cancers and drives resistance of ER+ tumors to endocrine therapy [26,28]. Using a mouse 
model of FGFR1 activation, we have shown that the loss of STAT5 in macrophages 
accelerates the formation of hyperplasias.  
 
The creation of luciferase has provided an invaluable tool to model tumorigenesis 
in vivo. In typical orthotopic transplant models, tumor cells are injected into the 
mammary fat pad and monitored for weeks before palpable masses are observed. Because 
of this long delay between transplant and detection of lesions, it is virtually impossible to 
determine if cells were successfully implanted and subsequently failed to engraft or if the 
transplant was unsuccessful from the start. Live-animal imaging using BLI has allowed 
us to address, with certainty, the question of transplant success. We observed no 
difference in luciferase signal between either genotype immediately after transplant, 
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suggesting that transplants were successful and that approximately the same number of 
cells were implanted. However, the gradual loss of luciferase signal in the STAT5fl/fl 
mice compared to the STAT5ΔMϕ mice and data from athymic nude mice suggest an 
active process responsible for tumor cell clearance. These observations would not be 
possible with traditional, non-labeled tumor cell transplantation. 
 
In these studies, we have identified that STAT5 signaling in macrophages is 
critical in regulating many factors that modulate anti-tumor immune responses. Targeted 
qRT-PCR has identified gene expression changes in STAT5-deficient macrophages. The 
small panel of genes studied is informative but suggests that larger-scale, genome-wide 
technologies must be employed to characterize the full spectrum of transcriptional 
changes regulated by STAT5. As discussed in Chapter 2, STAT5 is able to positively and 
negatively regulate different genes based on the recruitment of various chromatin 
remodeling factors. Our studies specifically focused on the mechanism underlying 
STAT5-mediated repression of PD-L2 expression. ChIP analysis demonstrated the 
potential for STAT5 to bind and repress expression at the Pdcd1lg2 locus, suggesting that 
the loss of STAT5 signaling in macrophages could lead to an immunosuppressive 
microenvironment that is permissive for tumor formation. 
 
By using autochthonous mouse models and syngeneic tumor cell lines, we have 
been able to use fully immunocompetent mice for these studies. This has enabled us to 
uncover and study mechanisms by which STAT5 signaling in macrophages regulates 
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adaptive immunity. These findings would not have been observed in 
immunocompromised mice, thus highlighting the critical need to develop additional 
tumor models to study the immune response. While using PD-L2 neutralizing antibodies 
in vivo has had a modest effect on detectable luciferase signal, there are not striking 
differences on caliper-measured tumor burden or overall survival. While these results 
remain preliminary, this may suggest that STAT5 regulates more than just PD-L2 
expression. Thus, it is entirely possible that overall tumor burden and survival are 
unaffected by anti-PD-L2 antibody treatment because STAT5 negatively regulates the 
production of soluble factors that promote tumorigenesis in a PD-L2-independent 
manner. Future studies will need to study the effects of these STAT5-repressed soluble 
factors on tumorigenesis and metastasis. 
 
The results from these studies appear to be somewhat counterintuitive. While 
tumor-derived soluble factors induce pro-tumorigenic changes in macrophages and 
STAT5 is activated by these same soluble factors, it does not appear that STAT5 is a pro-
tumorigenic signaling pathway in macrophages. In fact, it appears that STAT5 signaling 
in macrophages acts to restrain tumorigenesis by promoting adaptive immune responses. 
Indeed, by positively regulating T cell co-stimulatory factors such as CD86 and 
negatively regulating immunoregulatory factors like PD-L2, STAT5 signaling acts to tip 
the balance of T cell activation towards an anti-tumor response. However, STAT5 
signaling is only one pathway activated in TAMs and while it acts to promote anti-tumor 
immunity, other pathways may act to suppress this same immune response or regulate the 
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production of pro-tumorigenic soluble factors by TAMs. The net result of activating all 
these signaling pathways is an overall pro-tumorigenic response. Thus, more work is 
needed to characterize additional signaling pathways in TAMs that regulate 
transcriptional output and are responsible for controlling the balance between pro- and 
anti-tumor responses. 
 
In summary, the loss of STAT5 signaling in macrophages allows for the 
formation of a microenvironment which is permissive for mammary tumor initiation. 
Moreover, STAT5 deletion in macrophages cooperates with FGFR1 activation in 
mammary epithelial cells to accelerate tumor initiation, drive the formation of mammary 
gland hyperplasias, and promote tumor growth and progression. Further analysis reveals 
that STAT5 directly regulates the expression of immunomodulatory factors, such as PD-
L2, which can promote tumorigenesis through suppressing adaptive immune responses. 
Because activation of STAT5 and other members of the JAK/STAT signaling pathway 
have been linked to oncogenesis in breast cancer cells, there is currently a great interest in 
developing therapies to modulate the JAK/STAT signaling pathway. Ruxolitinib, an 
FDA-approved inhibitor of the JAK/STAT signaling pathway, is currently being explored 
in clinical trials with breast cancer patients. The results of these studies suggest that 
inhibition of this signaling axis in macrophages may lead to pro-tumorigenic changes in 
the microenvironment. While ruxolitinib has shown anti-tumor potential in pre-clinical 
work [272,273], knowing the on-target effects in non-tumor cells will help inform clinical 
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decision making in regards to combination therapies using ruxolitinib and other targeted 
therapies therapeutics. 
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Chapter 4. Inhibition of JAK/STAT Signaling in Macrophages Leads to 
Breast Tumor-Promoting Inflammation 
 
Introduction 
Over the past decade, tremendous advances have been made in next-generation 
sequencing (NGS) technology. These advances have greatly increased throughput of 
samples and dramatically reduced sample costs. Additionally, techniques have been 
developed to allow for the extraction and sequencing of nucleic acids from formalin-fixed 
paraffin embedded (FFPE) tissues, making available decades worth of pathology archive 
specimens for research use. The greater availability and declining cost of NGS raises the 
possibility of truly “personalized medicine”, whereby patients can have tumor tissue 
sequenced and all known targets of existing drugs queried to find the optimal 
combination of therapies. 
 
Developing new therapeutics is a process which can on average take more than 14 
years and cost more than $1 billion per drug [274,275]. Even more striking is the success 
rate of drugs moving from development to market approval, which currently stands at 
4.9% [276]. Thus, understanding why promising drugs fail during clinical trials is of 
critical importance. Many new drugs are found by analyzing thousands of compounds in 
silico and validating leads on breast cancer cells in vitro. One of the “gold standard” 
assays prior to clinical trials is testing drugs using in vivo tumor models. Often times, 
these models use human tumor cell lines or primary tissue xenograft in mice to test drug 
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efficacy. The successful growth of these cell in vivo, however, requires the use of highly 
immunodeficient mouse strains. The most common mouse strain used in these 
experiments is NOD/SCID/γc mice, which lack functional B and T lymphocytes as well 
as NK cells. While the use of these models advances research along the translational 
spectrum to model human disease, the lack of a functional immune system severely 
hinders studying the effect of drugs on anti-tumor immunity and can lead to failure 
during clinical trials [277]. 
 
Recent efforts have focused on developing new treatments which target critical 
pathways in breast cancer cells in order to improve patient outcomes. The role of 
JAK/STAT signaling in tumor cells has been well-studied and demonstrated to be critical 
for the promotion of tumor growth. Activation of STAT3 induced by IL-6 has been 
shown to promote the growth and renewal of stem-cell like breast cancer cells [273]. 
Additionally, the JAK/STAT signaling pathway has been implicated in promoting 
resistance to PI3K inhibitors in TNBC [272]. However, the role of JAK/STAT signaling 
in cells of the tumor microenvironment is less-well-characterized. Only recently, data 
have emerged suggesting that inhibition of JAK/STAT signaling leads to reduced NK 
cell-mediated tumor immune surveillance [278]. Based on these recent findings and the 
fact that TAMs are critical components of the tumor microenvironment, there is a clear 
need to understand of the role of JAK/STAT signaling in TAMs. 
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Therapeutic targeting of JAK/STAT signaling is currently being explored in 
breast cancer patients with the use of ruxolitinib, a JAK1/2-selective inhibitor that is 
currently FDA-approved for the treatment of myeloproliferative disorders [279,280]. Pre-
clinical studies using ruxolitinib have demonstrated potent anti-tumor activity against 
breast cancer cells [272,273]. Based on these promising results, ruxolitinib has been 
introduced to Phase I or II clinical trials for the use in breast cancer patients. Currently, 
there are 9 registered clinical trials using ruxolitinib and, while these trials are in their 
early stages, the first reported results demonstrate less than desired outcomes 
(NCT01562873). While discouraging, these studies do not address that treatments like 
ruxolitinib are disseminated systemically, and thus can affect signaling in non-tumor cells 
as well. Without knowing the targets of JAK/STAT signaling in non-tumor cells, 
particularly in TAMs, it is possible that ruxolitinib treatment may induce deleterious gene 
expression changes in an “on-target, off-cell type” manner. Indeed, studies performed in 
Chapter 3 highlight the potential pro-tumorigenic consequences of STAT5 inhibition in 
TAMs. Thus, understanding how inhibitors like ruxolitinib alter components of the tumor 
microenvironment will provide targets for novel combination strategies to further 
enhance outcomes for breast cancer patients. The studies described in this Chapter seek to 
address whether the presence of macrophages can affect the therapeutic efficacy of 
ruxolitinib and characterize transcriptional changes induced in macrophages by tumor-
derived soluble factors and ruxolitinib using genome-wide RNA-seq approaches. 
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Materials and Methods 
Mice. Wild-type female mice on the BALB/c background at 4 weeks of age were 
purchased from Envigo and maintained in specific pathogen free facilities. Mice were 
anesthetized with isoflurane and 1x105 4T1-luc cells suspended in 50% Matrigel (BD 
Biosciences) were injected into the fourth inguinal mammary fat pad. Tumor burden was 
measured every other day by calipers. When tumors reached 500 mm3, mice were 
randomized to treatment groups. For JAK/STAT inhibition, mice received 60 mg/kg 
ruxolitinib (or DMSO control) in 1% Tween-20 daily via oral gavage. To deplete 
macrophages, mice received 0.8 mg clodronate liposomes (or control liposomes) per 
mouse via intraperitoneal injection as a loading dose, followed by 0.4 mg liposomes per 
mouse every 3 days via intraperitoneal injection. Two hours prior to sacrifice, mice were 
injected with 30 mg/kg BrdU by intraperitoneal injection. All animal care and procedures 
were approved by the IACUC of the University of Minnesota and were in accordance 
with the procedures detailed in the Guide for Care and Use of Laboratory Animals. 
 
Breast cancer cell line culture. MDA-MB-231 cells were maintained in DMEM 
supplemented with 10% FBS and 1% penicillin/streptomycin (Life Technologies). MCF-
7 cells were maintained in the same media but were supplemented with 10 µg/mL insulin. 
 
Isolation of primary human peripheral blood mononuclear cells (PBMCs) and 
monocytes. Leukocyte reduction systems (Trima cones) were purchased from Memorial 
Blood Center (St. Paul, MN) and were obtained the day following collection from healthy 
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donors. Blood from the Trima cone was collected by flushing PBS through the device. 
Buffy coats were isolated via density gradient centrifugation with Isolymph solution 
following the manufacturer’s recommended protocol. Buffy coats were washed twice in 
PBS and CD14+ monocytes were isolated using magnetic human CD14 Microbeads 
(Miltenyi Biotec) following the manufacturer’s recommended protocol. 
 
Differentiation of human macrophages. For RNA and protein studies, 1x106 CD14+ 
monocytes were plated per well of a 12-well plate in RPMI supplemented with 10% FBS 
and 1% penicillin/streptomycin (Life Technologies) and treated for 5 days with 60 ng/mL 
rhCSF1 (Biolegend). After 5 days, cells were given an additional 60 ng/mL rhCSF1 and 
incubated for 3 days. Macrophages were pre-treated with ruxolitinib as indicated (or 
DMSO control) for 4 hours in serum-free RPMI before treatment with breast cancer cell 
conditioned media (CM) in the presence of ruxolitinib (or DMSO control) as indicated.  
 
Immunoblot analysis. Protein lysates were subjected to SDS-PAGE using 20 µg total 
protein. Immunoblot analysis was performed using antibodies listed in the Appendix. 
 
qRT-PCR. Cells were cultured as described above, RNA harvested using TriPure 
Reagent (Roche) and qRT-PCR was done as previously described [67] using qScript 
cDNA SuperMix and PerfeCTa SYBR Green SuperMix (Quantabio). Gene expression 
was normalized to PPIB (cyclophilin B) levels. Primers used are listed in the Appendix. 
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RNA-seq analysis. Total RNA was collected using TriPure reagent (Roche) and samples 
in biological triplicate were submitted to the University of Minnesota Genomics Center 
for quality control, library creation and next-generation sequencing. To pass quality 
control, at least 500 ng of RNA determined by RiboGreen Quantification and an RNA 
integrity number (RIN) of at least 8.0 as determined by Agilent 2200 TapeStation was 
required. Strand-specific RNA-seq libraries were created using TruSeq Stranded mRNA 
Library Prep Kit (Illumina) and quality control was performed using PicoGreen 
Quantification and Agilent 2200 TapeStation sizing. Samples were multiplexed in one 
lane of an Illumina HiSeq 2500. 50bp FASTQ paired-end reads (n=12.5 million per 
sample) were trimmed using Trimmomatic (v 0.33) enabled with the optional “-q” option 
(3bp sliding-window trimming from 3’ end requiring minimum Q30). Quality control on 
raw sequence data for each sample was performed with FastQC. Read mapping was 
performed via Bowtie (v2.2.4.0) using the UCSC human genome (hg19) as reference. 
Gene quantification was done via Cuffquant for fragments per kilobase of transcript per 
million mapped reads (FPKM) values and Feature Counts for raw read counts. 
Differentially expressed genes were identified using the edgeR (negative binomial) 
feature in CLCGWB (Qiagen) using raw read counts. Results were filtered based on a 
minimum 2x Absolute Fold Change and False Discovery Rate (FDR) corrected p < 0.05. 
 
Gene Set Enrichment Analysis (GSEA). Filtered FPKM values were subjected to 
GSEA v.2.2.4 (Broad Institute) [281,282]. Gene set collections were obtained from the 
Molecular Signatures Database (MSigDB) and included C3:motif, c5:gene ontology and 
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c7:immunologic gene sets. Analysis was performed by ranking genes using the 
Signal2Noise metric with 1000 random permutations and restricting gene set collection 
size to between 10 and 5000 genes.  
 
Results 
Depletion of Macrophages Enhances the Therapeutic Efficacy of Ruxolitinib 
Given that macrophages are important components of the tumor 
microenvironment and that loss of STAT5 in macrophages accelerates tumorigenesis, 
studies were performed to address whether the presence of macrophages would reduce 
the therapeutic efficacy of ruxolitinib. Wildtype BALB/c mice were injected with 4T1-
luc cells and tumors were allowed to reach 500 mm3 before being randomized to 
treatment groups as indicated and were subsequently followed until tumors reached 1 cm3 
(Figure 4.1A). Analysis of control mice demonstrated that 4T1-luc tumors grow very 
rapidly. Ruxolitinib treatment did not prolong overall survival of mice, nor did depletion 
of macrophages using clodronate liposomes. Surprisingly, however, depletion of 
macrophages in conjunction with ruxolitinib treatment led to a significant increase in 
overall survival (Figure 4.1B). Immunofluorescence analysis of tumor tissue sections 
revealed an overall decrease in the amount of F4/80+ macrophages in the tumors from 
clodronate liposome treated animals (Figure 4.2A). Additionally, spleen weight was 
assessed at time of sacrifice and significant reductions were observed in mice which 
received clodronate liposomes, further indicating macrophage depletion (Figure 4.2B). 
As a control, tumor weight was also assessed at time of sacrifice and no differences were  
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Figure 4.2. Clodronate-mediated depletion of macrophages 
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A) Immunofluorescent staining for F4/80 (red) and DAPI(blue) in 4T1 tumors from mice treated with control or 
clodronate liposomes. B) Quantification of spleen weight in mice treated as indicated at time of sacrifice. C) 
Quantification of tumor weight in mice treated as indicated at time of sacrifice. ***p<0.001, ****p<0.0001. 
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observed between treatment groups (Figure 4.2C). To verify the functional effect of 
ruxolitinib, levels of p-STAT3 were assessed by immunohistochemistry on tumor tissue 
sections. While still present, a large reduction in p-STAT3 staining was observed in 
tumor tissue from mice receiving ruxolitinib treatment (Figure 4.3). These data suggest 
that macrophages may mediate the therapeutic efficacy of ruxolitinib and further suggest 
that JAK/STAT inhibition in macrophages may promote tumor growth and progression. 
 
Ruxolitinib Blocks Tumor Cell-Induced STAT5 Activation in Human Macrophages 
Inhibiting the JAK/STAT signaling pathway can lead to a multitude of 
downstream effects. While transgenic mouse experiments using a conditional deletion of 
STAT5 in macrophages have been informative in elucidating a role from JAK/STAT 
signaling in TAM function, full characterization of the effects of ruxolitinib in human 
macrophages remains to be done. To begin addressing these effects, primary PBMCs 
were obtained from healthy donors and differentiated to macrophages. As a proof-of-
concept that tumor-derived soluble factors are able to activate JAK/STAT signaling in 
primary human macrophages, CM from the TNBC cell line MDA-MB-231 was collected 
and used to stimulate PBMC-derived macrophages. Analysis of protein lysates indicated 
strong activation of STAT5 signaling in human macrophages in response to tumor-
derived factors (Figure 4.4A). Initial studies were performed to identify changes in 
macrophage transcriptional output that were correlated with exposure to tumor cell-
derived soluble factors. Targeted qRT-PCR was performed on a small panel of genes 
previously implicated in promoting tumorigenesis. Gene expression analysis performed  
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Figure 4.3. Ruxolitinib reduces JAK/STAT activation in vivo 
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Immunohistochemical staining for p-STAT3 on tumor tissue sections from vehicle and ruxolitinib treated mice. 
Sections were counterstained with hematoxylin. 
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Figure 4.4. Tumor-derived soluble factors activate STAT5 signaling and regulate gene expression 
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A) Immunoblot of primary human macrophages treated with serum free media (SFM) or conditioned 
media from MDA-MB-231 cells (CM). β-tubulin shown as a loading control. B) mRNA expression of 
pro-tumorigenic factors in primary human macrophages from 4 independent donors after stimulation with 
serum free media (RPMI) or conditioned media from MDA-MB-231 cells (CM). 
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on macrophages derived from 4 independent healthy donors demonstrated that tumor-
derived soluble factors can induce the expression of tumor-promoting factors to varying 
degrees (Figure 4.4B). 
 
The gene expression data suggest that JAK/STAT signaling in macrophages may 
regulate the production of pro-tumor molecules but direct evidence using pharmacologic 
inhibitors of JAK/STAT signaling is needed to fully support this concept. In order to 
identify an optimal concentration of ruxolitinib to use for in vitro studies, a dose response 
was performed and 500 nM was found to be the lowest dose which was able to reduce 
tumor CM-induced STAT5 activation to untreated levels (Figure 4.5A). Importantly, this 
dose range corresponded to observed levels in serum of human patients receiving 
ruxolitinib in a clinical trial [283] and thus represents a biologically relevant dose. To 
further validate the observations in Chapter 3 regarding the breast cancer cell line CM-
induced STAT5 activation, studies were performed using CM from an additional cell 
line. As previously observed, MDA-MB-231 CM was able to robustly activate STAT5 
signaling, which was reduced with the addition of 500 nM ruxolitinib (Figure 4.5B). As 
observed in Chapter 3, treatment of macrophages with CM from the ER+ breast cancer 
cell line MCF-7 resulted in no observable activation of the STAT5 signaling pathway 
(Figure 4.5B). These data suggest that 500 nM ruxolitinib is an effective and clinically 
relevant dose for in vitro studies and that MDA-MB-231 and MCF-7 CM are appropriate 
for investigating the contributions of JAK/STAT signaling in human macrophages. 
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Figure 4.5. Ruxolitinib inhibits STAT5 activation in response to tumor-derived soluble factors 
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A) Immunoblot analysis of primary human macrophages stimulated with conditioned media from MDA-MB-231 
(231 CM) in the presence of increasing concentrations of ruxolitinib. GAPDH shown as a loading control. B) 
Immunoblot analysis of primary human macrophages stimulated with conditioned media from MDA-MB-231 
(231) or MCF7 cells in the presence of 500 nM ruxolitinib. GAPDH shown as loading control. 
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JAK/STAT Inhibition in Macrophages Induces Pro-Tumorigenic Changes 
While targeted qRT-PCR assays provided initial insight into the potential 
regulation of tumorigenesis by JAK/STAT signaling in macrophages, analyses performed 
on a genome-wide scale using NGS technology would allow for the full characterization 
of the transcriptional program that is dependent on JAK/STAT signaling. In order to 
obtain material for RNA-seq, the following experimental pipeline was established: 
PBMCs from healthy donors were isolated, CD14+ monocytes were enriched by MACS, 
macrophages were differentiated with CSF-1 and subsequently stimulated for 2 hours 
with CM from MDA-MB-231 or MCF-7 cells in the presence or absence of ruxolitinib, 
and total RNA harvested (Figure 4.6). RNA-seq data demonstrated that CM from MDA-
MB-231 cells significantly altered the expression level of over 2,000 genes in 
macrophages by greater than 2-fold, while CM from MCF-7 cells only altered 54 genes 
(data not shown). Initial efforts were focused on the most highly induced genes in 
macrophages, and thus the list of over 2,000 genes induced by MDA-MB-231 CM was 
ranked and the top 10 genes selected for further analysis. These genes included many 
secreted factors with known tumor-promoting functions, such as CSF3, CSF2, IL6, 
CXCL1 and CCL20 [266,284-288] (Figure 4.7A). Strikingly, in the presence of both 
MDA-MB-231 CM and ruxolitinib, the expression of 9 of the top 10 induced genes is 
further enhanced, suggesting that ruxolitinib treatment causes macrophages to increased 
their pro-tumor behavior (Figure 4.7B/C). 
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Figure 4.6. Overview of genomics experimental design 
Primary human peripheral blood mononuclear cells (PBMCs) were collected from healthy donors. Monocytes 
were purified using anti-CD14 magnetic separation strategies and macrophages were subsequently differentiated 
by treatment with CSF-1. Mature macrophages were treated +/- breast cancer tumor cell conditioned media (CM) 
along with ruxolitinib or solvent control. RNA was collected and submitted for RNA-seq at the University of 
Minnesota Genomics Center. 
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Figure 4.7. Ruxolitinib enhances the production of pro-inflammatory factors in TAMs 
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A) Heatmap of the top 10 most induced genes by RNA-seq in macrophages treated with tumor cell-derived soluble 
factors. B) Heatmap of the top 10 most induced genes by RNA-seq in macrophages treated with tumor cell-derived 
soluble factors in the presence of ruxolitinib. One sample was excluded from analysis due to low read counts for 
technical reasons. C) Quantification of the genes in B. **p<0.01, ***p<0.001, ****p<0.0001.  
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While assessing expression level of the most induced genes is informative, the 
genome-wide nature of the acquired data allows for much more thorough analysis. Using 
FPKM values, GSEA was performed to determine large-scale changes that may be 
occurring in macrophages in response to CM and ruxolitinib. As an initial screen, a gene 
set consisting of known binding motifs was queried to assess what transcription factors 
are involved in regulating the differentially-expressed genes. As expected, GSEA 
revealed an enrichment for genes known to be regulated by JAK/STAT signaling, 
specifically downstream of STAT1, STAT3 and STAT5 (Figure 4.8A). Also as expected, 
these STAT-binding motif gene signatures are not enriched in macrophages treated with 
ruxolitinib, suggesting that ruxolitinib is inhibiting the pathway appropriately (Figure 
4.8A). Additional gene sets were queried to assess tumor-promoting capabilities of the 
treated macrophages. Intriguingly, 2 pathways showed differential enrichment between 
the two groups: GO_REGULATION_OF_ADAPTIVE_IMMUNE_RESPONSE and 
GO_EPITHELIAL_CELL_PROLIFERATION (Figure 4.8B). In depth analysis of these 
gene sets revealed stark differences in tumor-promoting capabilities. MDA-MB-231 CM 
treatment led to the enrichment of genes involved in regulating the adaptive immune 
response, which was not observed upon ruxolitinib treatment, including TNFSF18, IL27, 
and CD40. CD40 is well-characterized co-stimulatory molecule that binds to CD40L on 
the surface of activated T cells and enhances immune activation [289]. IL-27 has been 
shown to promote TH1 responses while TNFSF18 (GITRL) has been implicated in 
promoting the expansion of T cell subsets [290,291]. In contrast, ruxolitinib treatment led 
to the enrichment of genes involved in epithelial cell proliferation, which was not 
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observed without ruxolitinib, including EREG, IL6, and WNT5A. These factors have all 
been shown to directly promote tumor cell proliferation and regulate tumor cell migration 
and invasion [266,292,293]. These data suggest that JAK/STAT inhibition in human 
TAMs can skew the transcriptional output to mount less of an anti-tumor adaptive 
immune response and directly promote tumor cell proliferation. 
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Figure 4.8. Transcriptional outputs which drive pro-tumor pathways are enriched in ruxolitinib-treated TAMs 
  
A 
B 
A) Gene Set Enrichment Analysis (GSEA) to identify transcription factor binding motifs associated with changes in 
gene expression in macrophages treated with tumor-derived soluble factors in the presence or absence of ruxolitinib. 
B) GSEA to identify pro-tumor changes in the TAM transcriptome in the presence of ruxolitinib. 
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Discussion 
Advances in drug discovery have increased overall survival in breast cancer 
patients over the past several decades [294]. Despite these successes, many drugs fail to 
show the desired efficacy in clinical trials. One limitation of current pre-clinical models is 
the that use of immunocompromised mice in human cell line xenograft or patient-derived 
xenograft models fails to provide a suitable testing environment for the contributions of 
immune cells. This is in direct conflict with the composition of the tumor 
microenvironment in patients, where immune cells play a critical role in regulating 
tumorigenesis. Moreover, the effects of systemically-delivered therapies on cells of the 
tumor microenvironment are unknown. The studies presented here illustrate the critical 
need for further understanding of the “on-target, off-cell type” effects of cancer 
therapeutics. Our studies have focused on the role of ruxolitinib, an inhibitor of 
JAK/STAT signaling. While ruxolitinib has shown promise as an anti-cancer therapeutic, 
studies documenting the effects of ruxolitinib on critical stromal components of the tumor 
microenvironment are lacking. Here, we demonstrate that macrophages can promote 
therapeutic resistance to ruxolitinib in an immunocompetent mouse model, suggesting 
that JAK/STAT inhibition in macrophages promotes a pro-tumor response in TAMs. 
Modeling the tumor microenvironment in vitro with the use of primary human 
macrophages and tumor cell CM, we have demonstrated that JAK/STAT signaling in 
robustly activated in macrophages treated with tumor CM, which can be blocked with the 
use of ruxolitinib. In addition to activating JAK/STAT signaling, tumor-derived soluble 
factors also induce the expression of pro-tumor factors in macrophages. On a global 
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scale, breast cancer CM is able to induce transcriptional changes that alter the expression 
of ~10% of the entire transcriptome. These induced changes include factors with known 
pro-inflammatory and pro-tumor functions. Finally, GSEA data demonstrates that whole 
pathways with pro-tumor consequences are altered by tumor-derived soluble factors and 
ruxolitinib. 
 
The use of ruxolitinib for the treatment of breast cancers is already under 
exploration in Phase I and II clinical trials. While 9 studies are registered using 
ruxolitinib as a drug in breast cancer, only 2 studies are actively recruiting while 6 have 
stopped recruiting or have yet to begin. Interestingly, one trial has already been 
terminated early and released results publically (NCT01562873). The design of the study 
stratified enrolled patients with high p-STAT3 levels in their tumors and the primary 
outcome measured was objective response rate, defined as a complete response with 
disappearance of all target lesions or a partial response showing at least a 30% reduction  
in the longest dimension of target lesions. Of the 21 patients enrolled in this trial, no 
patients completed the treatment regimen, with 20 of the 21 patients showing disease 
progression either clinically or by RECIST criteria. The remaining patient dropped out of 
the study due to treatment-related adverse events prior to evidence of disease progression. 
While this study focused only on patients with high p-STAT3 levels, expansion of the 
inclusion criteria to allow a second cohort of patients who showed intermediate levels of 
p-STAT3 staining was dropped after poor results in the first cohort. 
 
  151 
The failure of ruxolitinib in breast cancer was precisely recapitulated in our 
studies. Mice treated with ruxolitinib were indistinguishable from vehicle-treated mice, 
suggesting either a lack of efficacy of ruxolitinib on tumor cells or confounding effects 
from cells in the microenvironment. While we could restore therapeutic efficacy of 
ruxolitinib in our mouse studies with the depletion of macrophages, it remains to be seen 
whether macrophages contributed to the failure of ruxolitinib in clinical trials. Of 
additional note, this clinical trial did not identify a specific subtype of breast cancer for 
inclusion in the study. Our data suggest that JAK/STAT signaling is only activated in 
macrophages in response to soluble factors from TNBC, not ER+ or HER2+ tumors. Thus, 
it may be that ruxolitinib treatment of TNBC patients induces pro-tumorigenic changes in 
TAMs that may not be observed in the other subtypes. While the tumor subtypes of 
enrolled patients was not reported and overall response was poor, it may be informative 
to stratify the results by subtype to study whether the tumors of different histologic 
subtypes have an indication of differential response. 
 
Numerous gene expression changes in macrophages were induced by tumor-
derived soluble factors, including many with previously well-established tumor-
promoting functions. While gene expression was modulated both positively and 
negatively, the data analysis used in this work focused on the most highly-induced genes. 
This allows for the identification of novel therapeutic targets to be exploited with 
combination therapies. Many of the pro-tumor factors that are induced, such as IL-6 and 
EREG, are already the targets of FDA-approved therapies. Two monoclonal antibodies, 
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siltuximab for neutralizing IL-6 and tocilizumab for blocking the IL-6 receptor, are 
currently approved and undergoing clinical trials [295]. Additionally, EGFR blocking 
antibodies, including cetuximab, and small molecule tyrosine kinase inhibitors, such as 
gefitinib and erlotinib, have been developed and used clinically [296]. Drugs targeting G-
CSF and GM-CSF are still in early-phase testing and development [297]. Future studies 
will need to investigate the efficacy of these therapies in combination with ruxolitinib in 
immunocompetent animal models, as well as in human trials. In addition to genes 
induced in these studies, genes that were suppressed by tumor-derived factors and 
ruxolitinib are certainly worthy of further investigation. The loss of major T cell co-
stimulatory molecules in macrophages would suggest a loss of anti-tumor immunity. 
While harder to target therapeutically than molecules whose expression is induced, these 
downregulated genes can be investigated further to determine methods to restore their 
expression to normal levels. It should be noted that the immunocompromised mouse 
models used in most pre-clinical testing still retain macrophages. While this allows 
researchers to characterize some of the direct pro-tumor effects of macrophages, any 
macrophage-expressed factors which regulate T or B cell function are unable to be 
studied. Thus, researchers must be aware of this limitation while moving new drugs to 
clinical trials and new models must be developed to overcome this challenge. 
 
In summary, the data presented here demonstrate that macrophage can mediate 
therapeutic resistance to ruxolitinib in vivo. Using primary human macrophages, this 
work has shown tumor-derived factors activate STAT5 signaling and that using 
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clinically-relevant concentrations of ruxolitinib, this signaling can be blocked. 
Furthermore, ruxolitinib treatment further alters gene expression changes induced in 
macrophages by tumor-derived factors. These results indicate that ruxolitinib-treated 
macrophages lose the ability to promote anti-tumor immune responses and lead to the 
production of pro-tumor growth factors and cytokines. Future studies are warranted to 
investigate the use of ruxolitinib-induced molecules as therapeutic targets as combination 
therapies.  
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Chapter 5. Discussion 
 
Summary 
The overarching goals of this dissertation are to characterize how the STAT5 
signaling pathway in macrophages regulates mammary gland development and 
tumorigenesis and the clinical implications for therapeutic targeting of STAT signaling. 
Using transgenic mouse models, pharmacological inhibitors, primary human cells and 
genome-wide sequencing technology, we have identified a novel mechanism by which 
macrophages maintain tissue homeostasis in the developing mammary gland. Moreover, 
we have shown that the loss of STAT5 leads to the production of immunosuppressive 
molecules, suggesting that STAT5 signaling in macrophages regulates the interface of 
innate and adaptive immunity. Finally, we have highlighted the potential risks of clinical 
inhibition of JAK/STAT signaling in TAMs and identified novel therapeutic targets to 
use in combination with ruxolitinib. 
 
Studies performed in Chapter 2 were aimed at identifying novel regulators of 
macrophage function in the developing mammary gland. Many of the cytokines present 
in the mammary gland microenvironment utilize the JAK/STAT signaling pathway, and 
thus, we reasoned that macrophages present in this environment would also respond to 
these factors through JAK/STAT signaling as well. Microarray analysis of different 
tissue-resident macrophage populations indicated increased expression of Stat5a 
specifically in mammary gland macrophages. Immunostaining of mammary gland tissue 
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sections showed the presence of p-STAT5+ macrophages and suggested a potential role 
for STAT5 regulating the function of mammary gland macrophages. Taking a genetic 
approach, we generated mice lacking STAT5 in cells of the macrophage lineage. While 
deletion of STAT5 in macrophages did not affect macrophage recruitment to the 
mammary gland or epithelial cell differentiation, analysis of the pubertal mammary gland 
from these mice revealed a striking change in mammary gland development, 
characterized by reduced ductal elongation, increased lateral branching and increased cell 
proliferation. These changes were consistent with increased estrogen signaling in the 
mammary gland and were associated with increased expression of the ER target genes 
Ctsd, Wnt4, and Areg. Because number and distribution of ER+ cells in the mammary 
glands were unaffected, studies were performed to assess local production of estrogen in 
the mammary gland. STAT5-deficient macrophages demonstrated increased expression 
of Cyp19a1 (aromatase) and a putative STAT5 tetramer binding site was found in the 
Cyp19a1 gene. ChIP studies revealed the ability of STAT5 to bind this site under basal 
conditions to repress gene expression. Immunostaining of mammary gland tissue showed 
increased CYP19A1 expression in the mammary gland stroma from STAT5ΔMϕ mice. 
Moreover, we demonstrated increased expression of Il6 in STAT5-deficient 
macrophages. Additional ChIP studies revealed the role of IL-6 in the regulation of 
Cyp19a1 expression, whereby IL-6 induced Cyp19a1 expression in macrophages by 
altering the binding of STAT5 at the Cyp19a1 locus and promoting STAT3 binding 
instead. These studies uncovered a novel regulator of mammary gland macrophage 
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function and led us to ask whether perturbations in the mammary gland macrophages 
would predispose the tissue to oncogenic initiation. 
 
In Chapter 3, studies were performed to directly test if the loss of STAT5 in 
macrophages would affect tumor initiation, growth, and metastasis. To verify that STAT5 
signaling was activated in TAMs, macrophages were stimulated with CM from a variety 
of breast cancer cell lines in vitro. Immunoblot analyses revealed that STAT5 was 
activated in response to tumor-derived soluble factors from breast cancer cell lines and 
thus, we reasoned that STAT5 signaling could be relevant to tumorigenesis. Again using 
transgenic approaches, we generated mice lacking STAT5 in cells of the macrophage 
lineage that also carried an inducible oncogene in mammary epithelial cells. Using this 
model, we demonstrated that the loss of STAT5 signaling in macrophages cooperated 
with oncogenic activation of FGFR1 in MECs to promote tumor initiation. This was 
characterized by mammary gland hyperplasias, increased epithelial area, and increased 
cell proliferation in the hyperplastic lesions. In order to follow tumorigenesis 
longitudinally in vivo, we developed a transplantable tumor cell line that stably expressed 
firefly luciferase. After verifying the tumorigenicity of the cell line, these cells were 
transplanted into both STAT5fl/fl and STAT5ΔMϕ mice. Using BLI, we observed dramatic 
clearance of tumor cells from STAT5fl/fl mice that was not observed in STAT5ΔMϕ mice 
or athymic nude mice. Using parental HC-11/R1 cells, we demonstrated a striking 
decrease in overall survival of STAT5ΔMϕ mice and increased metastatic burden in the 
lungs. These results were also verified using the highly aggressive and metastatic 4T1 
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tumor cell line. We identified numerous transcriptional changes that occur upon the loss 
of STAT5 signaling in macrophages, many of which would have pro-tumorigenic 
consequences. Of interest was the increased expression of the immunoregulatory 
molecule Pdcd1lg2 (PD-L2) in STAT5-deficient macrophages. Analysis of the Pdcd1lg2 
locus revealed a STAT5 tetramer binding site that may suppress gene expression. ChIP 
studies demonstrated the ability of STAT5 to bind the locus under basal conditions and 
that this binding was not observed in STAT5-deficient macrophages. Functional studies 
to modulate PD-L2 activity in vivo are still in the preliminary stages, but have begun to 
demonstrate that neutralizing antibody treatment of STAT5ΔMϕ mice reduced luciferase 
signal nearly to levels observed in STAT5fl/fl mice. These results began to demonstrate 
the possible negative consequences of inhibiting STAT5 signaling in TAMs. 
 
Chapter 4 was focused on understanding the role of JAK/STAT signaling in 
macrophages and how pharmacologic inhibitors would change TAM function. The 
JAK/STAT inhibitor ruxolitinib is currently being using in breast cancer clinical trials. 
While 9 trials are currently registered using ruxolitinib in breast cancer, 1 of these trials 
has already ended in failure. We hypothesized that the “on-target, off-cell type” effect of 
ruxolitinib on TAMs may be responsible for this treatment failure. Using an orthotopic 
transplant of 4T1 mammary tumor cells into immunocompetent recipients, we 
demonstrated that ruxolitinib as a single agent gave no survival benefit to mice receiving 
the treatment, nor did depletion of macrophages with clodronate liposomes. However, the 
combination of ruxolitinib and macrophage depletion significantly extended overall 
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survival and demonstrated that macrophages could modulate the therapeutic efficacy of 
ruxolitinib in vivo. Signaling studies were carried out in primary human PBMC-derived 
macrophages and demonstrated that JAK/STAT signaling is activated in these 
macrophages by tumor-derived soluble factors. Additionally, this activation was blocked 
in vitro with the use of a clinically-relevant dose of ruxolitinib. Ruxolitinib-induced 
changes in the transcriptional output of macrophages was assessed with RNA-seq. These 
studies demonstrated the ability of tumor-derived soluble factors to directly regulate the 
transcription of approximately 10% of the entire human genome. Moreover, RNA-seq 
results indicated that many pro-tumorigenic factors were among the most highly induced 
genes. Additionally, ruxolitinib further enhanced the expression of these pro-tumorigenic 
factors in the macrophages. Using GSEA, we found that ruxolitinib treatment resulted in 
the loss of anti-tumor immune responses and the production of growth factors to directly 
promote tumor growth. All together, the results of Chapters 2 – 4 indicate a critical role 
of STAT5 signaling in macrophages during mammary gland development and 
tumorigenesis. 
 
Future Directions 
The completion of the studies in Chapter 2 have hinted at specific functions of 
mammary gland macrophages during pubertal development. However, much work 
remains to be performed to further increase the knowledge and understanding of specific 
signaling pathways that regulate mammary gland macrophage function directly. Our 
studies identified that STAT5 binds to the Cyp19a1 locus and suppresses gene expression 
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under basal conditions. However, upon IL-6 treatment, STAT5 is released from this 
binding site and Cyp19a1 is expressed. Despite these findings, direct mechanistic 
assessment of the function of macrophage-derived estrogen remains to be elucidated. 
Both STAT5fl/fl and STAT5ΔMϕ mice were systemically treated with tamoxifen to reduce 
estrogen binding to ER, and thus, reduce ER target gene expression (data not shown). 
The expectation was that reduced ER target gene expression in STAT5ΔMϕ mice would 
restore normal ductal elongation and MEC proliferation to wild-type levels. Complicating 
matters, however, was the fact that tamoxifen treatment blocked normal mammary gland 
development from occurring in the STAT5fl/fl mice. This is due, mainly, to the absolute 
requirement of estrogen during development. Thus, no comparisons could be made to 
determine the effect of tamoxifen on STAT5ΔMϕ mice. The most direct way to implicate a 
role for macrophages-derived estrogen would be through the use of Cyp19a1 floxed 
mice. To date, no Cyp19a1 floxed mice have reported in the literature. However, an 
embryonic stem (ES) cell line from C57BL/6 mice has been created carrying loxP sites 
surrounding a critical exon in the Cyp19a1 gene (Jackson Labs MGI: 4455643). Thus, 
generating mice from these ES cells would create Cyp19a1 floxed mice which can be 
bred with Csf1r-iCre mice. Deleting Cyp19a1 only in macrophages would allow for the 
assessment of macrophage-derived estrogen during mammary gland development.  
 
Currently, our immunostaining protocols using anti-aromatase and anti-F4/80 
antibodies are incompatible for co-staining approaches due to differential sensitivity to 
citrate-mediated antigen unmasking. Specifically, detection of aromatase requires antigen 
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unmasking to be carried out by boiling slides in citric acid for 20 minutes. At the same 
time, this process destroys the F4/80 antigen, rendering it undetectable by current 
immunochemical staining methods and limiting the ability to detect macrophage-
produced aromatase. Intriguingly, the targeting vector used in the ES cell line described 
above also contains a lacZ reporter element, allowing for Cyp19a1 expression to be 
marked by β-galactosidase staining. More importantly, β-galactosidase immunostaining 
can be performed without the use of antigen unmasking, allowing for immunofluorescent 
co-staining of aromatase-expressing macrophages through the use of anti-β-galactosidase 
and anti-F4/80 antibodies. 
 
The use of the Csf1r-iCre mice has allowed for the study of STAT5 function in 
macrophages. While Cre-mediated gene deletion occurs extremely efficiently in 
macrophages, Csf1r promoter expression is not strictly limited to macrophages [239], and 
thus, mitigating effects of STAT5 deletion in other cell types need to be addressed. An 
interesting observation made in the STAT5ΔMϕ mice was that inguinal lymph node size in 
the mammary gland was reduced by 50% compared to STAT5fl/fl littermate controls (data 
not shown). Intriguingly, mice carrying a targeted deletion of STAT5 in DCs through the 
use of Cd11c-Cre also have a 50% reduction in inguinal lymph node size [228]. These 
similarities suggest overlap between the Csf1r-iCre and Cd11c-Cre, presumably in the 
myeloid-derived DC population. It is currently unknown how this population regulates 
lymph node size or how STAT5 would regulate this process. Importantly, no striking 
abnormalities were noted in mammary gland development using the Cd11c-Cre mice, 
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suggesting that the unintended deletion of STAT5 in myeloid-derived DCs is not 
contributing to the reduced ductal elongation and increased branching observed in the 
STAT5ΔMϕ mice. At the same time, however, it would be informative to use additional 
mouse models using Cre driven by other cell type-specific promoters. It has been 
reported that Csf1r-iCre can lead to partial deletion of floxed genes in a subset of T cells 
[239] and recent work has implicated CD4+ T cells in mammary gland development 
[234]. Thus, future studies will need to assess the overlap of Cd4-Cre and Csf1r-iCre and 
determine the consequences of the partial loss of STAT5 in a subset of T cells. 
  
While immunohistochemical staining identified increased stromal aromatase 
expression, we were unable to definitively show co-staining with macrophages for the 
technical reasons discussed above. However, given the data that STAT5-deficient 
macrophages produce more Il6, which has been previously shown to induce Cyp19a1 
expression in stromal cells [166], it is important to tease apart contributions to estrogen 
biosynthesis from macrophages and other stromal cells, such as fibroblasts and 
adipocytes. By crossing the Cyp19a1 floxed mice described above with a fibroblast-
specific Cre, such as Fsp1-Cre [298], or an adipocyte-specific Cre, such as Adipoq-Cre 
[299], we will be able to determine the contributions of non-macrophage stromal cells to 
the production of aromatase and the effects on mammary gland development. 
 
The studies in Chapter 2 focused exclusively on the role of STAT5 signaling in 
macrophages during pubertal development. However, additional characterization of the 
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function of STAT5 in macrophages during other critical mammary gland stages is 
essential. As a secretory organ, the mammary gland is responsible for secreting milk 
during lactation. This process is also regulated by hormone signaling, primarily through 
prolactin. As with IL-4 and IL-13 in the developing mammary gland, prolactin also 
activates STAT5 signaling in MECs. Additionally, STAT5 is required for signaling 
downstream of the prolactin receptor, as mice with STAT5-deficient MECs fail to lactate 
[95]. Interestingly, human macrophages have been shown to express the prolactin 
receptor during times of inflammation [300]. Thus, the potential exists that prolactin-
responsive macrophages exist in the lactating mammary gland. No studies have 
investigated the effects of prolactin on macrophages during lactation but it is tempting to 
speculate that STAT5 would be a critical regulator of this signaling pathway. After 
lactation and weaning, the mammary gland must undergo a process of involution to 
return to the resting, pre-lactation state. This process requires coordinated cell death of 
the mammary epithelium and is regulated by the cytokine leukemia inhibitory factor 
(LIF) in a STAT3-dependent manner [301]. Ablation of macrophages during involution 
revealed that macrophages are required to regulate the processes of epithelial cell 
apoptosis and adipocyte regrowth [143]. As with lactation, the role of STAT5 signaling 
in macrophages during involution has yet to be investigated. Because macrophages 
express the LIF receptor, it is entirely possible that LIF in the microenvironment during 
involution can also affect macrophages. Data from Chapter 2 demonstrate opposing 
regulation of Cyp19a1 between STAT3 and STAT5, where genomic binding of one 
factor may prevent binding by the other. As LIF signals downstream through STAT3, it is 
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possible that STAT5 may be involved in regulating this pathway and that the loss of 
STAT5 signaling in macrophages may have effects on involution. Observations from the 
STAT5ΔMϕ mouse breeding colony have shown that pups born to STAT5ΔMϕ dams are 
able to nurse successfully and thrive, suggesting that lactation is not completely inhibited 
due to the loss of STAT5 in macrophages. Interestingly, while the first litter born to a 
STAT5ΔMϕ dam show no developmental defects, all subsequent litters appear slightly 
smaller compared to litters born to STAT5fl/fl dams. This evidence is purely anecdotal in 
nature and studies that properly control for litter size remain to be performed. 
 
The study of STAT5-mediated regulation of Cyp19a1 expression only scratched 
the surface of the genome-wide regulatory functions of STAT5. We focused our 
mechanistic studies on Cyp19a1 due to its role in estrogen biosynthesis and the 
phenotype observed in the STAT5ΔMϕ mammary glands. Without a doubt, STAT5 binds 
and regulates numerous genetic loci and future studies need to be performed utilizing 
ChIP-seq techniques to fully characterize these binding sites. These studies will most 
likely require the use of BMDMs stimulated with CM from mammary epithelial cell 
lines, as was performed in Chapter 2. While previous studies have demonstrated that 
BMDMs serve as a good in vitro model of mammary gland macrophages [143], the best 
approach would be to isolate macrophages directly from the mammary gland. Performing 
ChIP directly on isolated macrophages ex vivo is not optimal, as the amount of time 
required for isolating the cells will undoubtedly alter STAT5 signaling and binding. 
However, using FACS and sorting F4/80+ cells from the mammary glands, the 
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macrophages can be grown briefly in culture before being stimulated with CM from 
mammary epithelial cells to reactivate STAT5 signaling. In addition to performing 
STAT5 ChIP-seq, future studies can also utilize STAT3 ChIP-seq to assess competition 
for binding sites and opposing regulation between the two transcription factors. Our 
studies in Chapter 2 revealed the potential for STAT3 and STAT5 to compete for binding 
at the Cyp19a1 locus but other such regulated loci in macrophages remain to be 
characterized. 
 
The tumor models used in Chapter 3 revealed that the loss of STAT5 signaling in 
macrophages led to enhanced tumorigenesis. While the mechanistic studies focused on 
the regulation of PD-L2, altering an entire signaling pathway via genetic deletion would 
undoubtedly have genome-wide consequences. Targeted qRT-PCR panels in Chapter 3 
demonstrated that STAT5 regulates many different soluble factors with known pro-tumor 
functions. Thus, further studies utilizing RNA-seq are warranted to fully characterize the 
transcriptome of STAT5-deficient TAMs. 
 
In their function as APCs, macrophages are critical regulators of the adaptive 
immune system. The ability to process and present antigen allows macrophages to help 
initiate immune responses by T cells. The gene expression data from macrophages in 
Chapter 3 indicate that STAT5 regulates both T cell co-stimulatory and 
immunoregulatory molecules. While these data suggest that STAT5 signaling in 
macrophages may regulate T cell-mediated immune responses, further work is needed to 
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definitively prove this. A co-culture system using BMDM and primary T cells from 
STAT5fl/fl and STAT5ΔMϕ would allow for the functional validation of the role of STAT5 
signaling in regulating adaptive immunity. T cells would be labeled with CFSE, a dye 
that allows for the tracking of cell division by flow cytometry, then stimulated with αCD3 
and αCD28 antibodies to activate T cell signaling. Based on observations of tumor 
growth in Chapter 3, we expect to see robust T cell proliferation in the presence of 
STAT5fl/fl macrophages and reduced T cell proliferation in the presence of STAT5ΔMϕ 
macrophages. Furthermore, a co-culture system would allow for the testing of 
therapeutics in vitro to enhance anti-tumor immunity and overcome the STAT5-mediated 
immunosuppression induced in macrophages.  
 
The studies performed in Chapter 4 revealed some striking and potentially 
detrimental side-effects of JAK/STAT inhibition in macrophages. Using an 
immunocompetent mouse model of mammary tumorigenesis, we have demonstrated that 
macrophages are key influencers of the efficacy of ruxolitinib. Additionally, those results 
recapitulated the observations made in the failed clinical trial of ruxolitinib in breast 
cancer patients, namely that ruxolitinib as a single-agent had no therapeutic benefit 
(NCT01562873). While we were able to deplete macrophages and restore efficacy in our 
mouse model, the clinical trial was not designed with macrophage targeting in mind. 
While we can currently only speculate on the role of macrophages in the clinical trial 
failure, access to patient tissue samples from the clinical trial would be extremely 
informative. FFPE tissue blocks could be used with immunostaining techniques to 
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identify TAMs and the effect of ruxolitinib on their function. Specifically, we can attempt 
to validate the genes induced by ruxolitinib in the RNA-seq studies using the human 
tissue samples. This will demonstrate the effectiveness of using human PBMC-derived 
macrophages as in vitro models of TAM function and potentially implicate TAMs as the 
major contributor to the limited efficacy of ruxolitinib in breast cancer clinical trials. 
 
A prudent next step in translating the findings of Chapter 4 to have a clinical 
impact is to further study the ruxolitinib-induced genes and modulate levels 
therapeutically in vivo. In conjunction with assessing the expression of these genes from 
available patient samples, these genes also need to be measured in ruxolitinib-treated 
tumors from our mouse model studies. As that model mimics the clinical findings, it 
would be satisfying to find similar results in vivo as was found from the RNA-seq studies. 
Additionally, targets identified by RNA-seq with confirmed expression in the mouse 
model can be tested in combination therapies with ruxolitinib. As a first step, more 
clinically-relevant methods of modulating macrophage levels, such as CSF1R blocking 
antibodies, can be used to validate the clodronate liposome data. Then, by replacing the 
CSF1R blocking antibodies with therapies directed against ruxolitinib-induced targets in 
TAMs, we will be able to test how modulating these factors can improve the therapeutic 
efficacy of ruxolitinib. Successful results in these animal studies would be rationale for 
further investigation of these agents, with additional pre-clinical work and eventually 
clinical trials. 
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While the results of the RNA-seq studies revealed the ability of ruxolitinib to 
induce pro-tumorigenic gene transcription in human macrophages, this technique is 
ignorant of the transcription factors upstream that modulate these genes. Further studies 
utilizing ChIP-seq are warranted to completely characterize the role of JAK/STAT 
signaling in human macrophages. This approach is technically challenging, both in terms 
of the assay and chromatin preparation, as well as simply having access to enough cells to 
obtain sufficient quantities of DNA. This is further compounded with the use of primary 
human cells, as opposed to cell lines, where growth kinetics and adaptation to tissue 
culture plastic and relatively understudied and PBMC quantity is limited. The studies 
performed in Chapter 4 have utilized an uncommon source of PBMCs, leukocyte 
reduction systems. The benefits of this source include low cost, availability from local 
sources, and relative ease of PBMC isolation. However, these sources are typically 
single-use and repeated collection of the same donor is not possible. Commercially-
available sources of PBMCs allow for the purchase of much larger quantities, but 
typically come with correspondingly larger prices. In addition to performing ChIP-seq for 
members of the JAK/STAT pathway, assessing how ruxolitinib affects chromatin 
modifications can also be studied. It is well-characterized that STAT5 can recruit the 
histone methyltransferase EZH2 and repress gene transcription [247,256]. Thus, it would 
be informative to assess histone modifications on a global-scale and identify any potential 
changes that could also be targeted therapeutically.  
 
  168 
One area of research that remains to be explored is the identification of the 
specific tumor-derived factors that activate STAT5 in macrophages. As shown in 
Chapters 3 and 4, CM from breast cancer cell lines is able to activate STAT5 signaling in 
macrophages. We have also shown that this activation is JAK-dependent, as treatment 
with ruxolitinib can block STAT5 activation. Thus, the upstream activating factors are 
likely to be cytokines that bind to receptors with associated JAKs that mediate 
downstream signaling. The RNA-seq data from Chapter 4 has the potential to help 
identify these unknown factors. Using Ingenuity Pathway Analysis, we have queried our 
list of induced and repressed genes and used computational modeling to predict the 
potential upstream regulators. This analysis has revealed that one of the most likely 
mediators of STAT5 activation in the CM from MDA-MB-231 cells is triggering receptor 
expressed on myeloid cells 1 (TREM1). The TREM1 signaling pathway is known to use 
JAK2 and STAT5 [302] to carry out downstream signaling and to induce the expression 
of pro-inflammatory genes. The presence of TREM1 ligands in the MDA-MB-231 CM 
remains to be validated and levels must be therapeutically modulated to explore the 
function of TREM1-induced signaling in macrophages. In addition to IPA performed on 
the RNA-seq data, direct proteomic analysis on the CM will help to identify other 
additional regulators of STAT5 activation and allow for further studies of their roles in 
regulating TAM function. 
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Conclusions 
The studies performed in this dissertation have focused on the role of STAT5 
signaling in macrophages during different environmental contexts. We have 
demonstrated that STAT5 controls macrophage function in the developing mammary 
gland by regulating aromatase expression and estrogen signaling. Using autochthonous 
and transplant models of mammary tumorigenesis, we have shown that STAT5 signaling 
regulates tumor-associated macrophage function by modulating the expression of 
immunoregulatory and co-stimulatory molecules. Finally, these studies have 
demonstrated the ability of a clinically-relevant JAK/STAT inhibitor to induce the 
expression of pro-tumorigenic factors in macrophages and have demonstrated the need to 
understand the effects of systemic therapies on other cells in the tumor microenvironment 
(Figure 5.1). 
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Appendix 
Appendix Table A1. Antibodies used for immunoblot analysis, immunohistochemistry, 
immunofluorescence and FACS: 
 
Antibody Catalog # Antigen Retrieval Dilution 
AREG AF989 (R&D) Y 1:250 (IF) 
Aromatase ab18995 (Abcam) Y 1:200 (IHC) 
β-tubulin 2146 (Cell Signaling) N/A 1:1000 (WB) 
BrdU ab6326 (Abcam) Y 1:300 (IF) 
CD45-PE/Cy7 103113 (Biolegend) N/A 1:100 (FACS) 
ERα sc-542 (Santa Cruz) Y 1:250 (IHC) 
F4/80 MCA497GA (AbD Serotec) N 1:100 (IF/IHC) 
F4/80-APC 20-4801-U025 (Tonbo Biosciences) N/A 1:100 (FACS) 
GAPDH 2118 (Cell Signaling) N/A 1:1000 (WB) 
K8 TROMA-I (DSHB/Univ of Iowa) Y 1:250 (IF) 
K14 PRB-155P (Covance) Y 1:500 (IF) 
STAT3 12640 (Cell Signaling) N/A 1:1000 (WB) 
p-STAT3 (Paraffin) 9145 (Cell Signaling) Y 1:200 (IHC) 
p-STAT3 (WB) 9131 (Cell Signaling) N/A 1:1000 (WB) 
STAT5 (Paraffin) 9358 (Cell Signaling) Y 1:200 (IHC) 
STAT5 (WB) 9358 (Cell Signaling) N/A 1:1000 (WB) 
p-STAT5 (WB) 9359 (Cell Signaling) N/A 1:1000 (WB) 
p-STAT5 (Cryo IF) 9359 (Cell Signaling) N 1:50 (IF) 
p-STAT5 (Paraffin) 9359 (Cell Signaling) Y 1:200 (IHC) 
Viability-APCef780 65-0865-14 (eBiosciences) N/A 1:500 (FACS) 
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Appendix Table A2. Mouse primer sequences used in qRT-PCR and ChIP: 
 
Gene Primer Sequence (5’ → 3’) 
Areg Forward: GGGGACTACGACTACTCAGAG 
Reverse: TCTTGGGCTTAATCACCTGTTC 
Cdh1 Forward: CAGTTCCGAGGTCTACACCTT 
Reverse: TGAATCGGGAGTCTTCCGAAAA 
Cd44 Forward: TCTGCCATCTAGCACTAAGAGC 
Reverse: GGGAAGAGAGTCCCATTTTCCA 
Cd86 Forward: TCTCCACGGAAACAGCATCT 
Reverse: CTTACGGAAGCACCCATGAT 
Cldn3 Forward: ACCAACTGCGTACAAGACGAG 
Reverse: CAGAGCCGCCAACAGGAAA 
Cldn4 Forward: GTCCTGGGAATCTCCTTGGC 
Reverse: TCTGTGCCGTGACGATGTTG 
Cldn7 Forward: GGCCTGATAGCGAGCACTG 
Reverse: GTGACGCACTCCATCCAGA 
Ctsd Forward: GCTTCCGGTCTTTGACAACCT 
Reverse: CACCAAGCATTAGTTCTCCTCC 
Cyclophilin B Forward: TGAGCACTGGGGAGAAAGG 
Reverse: TTGCCATCCAGCCACTCAG 
Cyp19a1 (mRNA) Forward: ATGTTCTTGGAAATGCTGAACCC 
Reverse: AGGACCTGGTATTGAAGACGAG 
Cyp19a1 (ChIP) Forward: ACTAGAAGTGACCAGCAGATCC 
Reverse: CCCTCTTCTCTTCTCACATCAG 
Il6 Forward: TAGTCCTTCCTACCCCAATTTCC 
Reverse: TTGGTCCTTAGCCACTCCTTC 
Pdcd1lg2 (mRNA) Forward: TAAAGAAGTGTACACCGTAGACGTC 
Reverse: TCATTTTCTACCTTCTGCAAACTGG 
Pdcd1lg2 (ChIP) Forward: TGCCAATTAAACTTCCCTAACCG 
Reverse: AGGCTGAAAGGGGAGAATCTAG 
Snai1 Forward: CACACGCTGCCTTGTGTCT 
Reverse: GGTCAGCAAAAGCACGGTT 
Stat5a Forward: CGCTGGACTCCATGCTTCTC 
Reverse: GACGTGGGCTCCTTACACTGA 
Stat5b Forward: GGACTCCGTCCTTGATACCG 
Reverse: TCCATCGTGTCTTCCAGATCG 
Wnt4 Forward: AGACGTGCGAGAAACTCAAAG 
Reverse: GGAACTGGTATTGGCACTCCT 
 
 
  
  196 
Appendix Table A3. Human primer sequences used in qRT-PCR: 
 
Gene Primer Sequence (5’ → 3’) 
CCL22 Forward: ATCGCCTACAGACTGCACTC' 
Reverse: GACGGTAACGGACGTAATCAC 
Cyclophilin B Forward: TGAGCACTGGGGAGAAAGG 
Reverse: TTGCCATCCAGCCACTCAG 
IL10 Forward: GACTTTAAGGGTTACCTGGGTTG 
Reverse: TCACATGCGCCTTGATGTCTG 
PDCD1LG2 Forward: CTGGGACTACAAGTACCTGACTCTG 
Reverse: GTGAGCTCTACCTCATCTGTTTCTG 
TNFA Forward: AGGTCCGAAAACACTGTGAGT 
Reverse: AGCAAGCGGTTCTTCCCTTC 
 
